



## INDEX

Page numbers followed by *t* indicate tables; those followed by *f* indicate figures; those followed by *b* indicate boxes.

- A**
- Abdomen
    - newborn, 464–465, 468t
    - in prenatal physical examination, 262
  - Abortion
    - ANA code of ethics and, 15, 16
    - defined, 91
    - ethical conflicts and, 15, 16
    - medical, 91
    - modalities for, 16
    - surgical, 91
  - Abruptio placenta
    - assessment of, 514
    - classification of, 513, 513f
    - clinical manifestations of, 513
    - definition of, 512
    - disseminated intravascular coagulation and, 513–514, 514b
    - emergency care for, 604
    - fetal mortality rate for, 512
    - interventions in, 514–515
    - risk factors for, 512–513
    - treatment of, 513–514
  - Abstinence contraception, 76, 77f
  - Abuse. *See also* Violence
    - abusers in, 193
    - assessment for
      - questions about, 200
    - characteristics of, 191
    - isolation of patient from family, 198, 200
    - management of
      - assessment of rape survivors for PTSD, 200
      - documentation and reporting of findings, 200–201, 202f–203f
      - education about community services, 201, 204
      - emotional support in, 204
      - interventions, 201, 204b
      - isolate victim from family, 198, 200
      - questions about, 200
      - safety assessment, 201
      - safety plan in, 204
      - SAVE model for, 200b
      - screening for abuse, 198
    - nursing diagnoses in, 201
    - screening for, 198
    - types of, 191–192
    - victims in, 193
  - Access to health care
    - barriers to, 14
    - Kaiser Women’s Health study, 13–14, 14b
  - Acquaintance rape, 194
  - Acquired disorder(s)
    - from birth trauma, 680–681
    - bronchopulmonary dysplasia, 671–672
    - hyperbilirubinemia, 687–693
    - in infants of diabetic mothers, 675–679.
      - See also* Infants of diabetic mothers
    - meconium aspiration syndrome, 669–670
    - national health goals related to, 665
    - necrotizing enterocolitis, 673–675
    - neonatal asphyxia, 664–666, 666b
    - periventricular–intraventricular hemorrhage, 672–673
    - persistent pulmonary hypertension, 670–671
    - respiratory distress syndrome, 666f, 667–669
    - from substance abusing mothers, 681–687. *See also* Alcohol use/abuse; Substance use/abuse
    - transient tachypnea of the newborn, 666–667
  - Acrocyanosis, 460
  - Acupressure, in labor, 348–349
  - Acupuncture, in labor, 348–349
  - Addiction, impact of, 574–575
  - Adolescence
    - described, 567
    - developmental tasks of, 567f, 567–568
  - Adolescent pregnancy
    - assessment in, 569
    - cost of, 569
    - health and social consequences of, 568
    - impact on adolescence, 568
    - incidence of, 568
    - interventions in, 569–570, 570f
    - national health goals related to, 568
    - risk factors for, 568
    - teaching prevention of, 570b
  - Adrenal glands, in pregnancy, 244
  - Afterpains, 381
  - Age over 35 years, pregnancy and, 570–571
  - AIDS (acquired immunodeficiency syndrome). *See also* HIV (human immunodeficiency virus) infection
    - from HIV infection, 572
    - incidence and prevalence of, 571
    - in pregnancy, 571
  - Alcohol use/abuse
    - alcohol-related birth defects from, 682
    - effect on pregnancy, 575t
    - fetal alcohol syndrome from, 682–683
    - in pregnancy
      - fetal effects of, 575–576, 576b, 576f
      - screening for, 576
  - Aldosterone, in pregnancy, 244
  - Alpha-fetoprotein (AFP) analysis, in fetal assessment, 268–269
  - Ambulation, in labor, 348, 349f, 350t–351t
  - Amenorrhea
    - assessment of, 61
    - definition of, 60
    - etiology of, 60–61
    - lifestyle changes for, 61, 62
    - management of, 61
    - treatment of, 61
  - Amniocentesis
    - for chromosomal abnormalities, 269
    - fluid analysis and implications, 271t
    - for genetic abnormalities, 269
    - management following, 271
    - in second trimester, 269–270
    - technique for, 270, 270f
  - Amnioinfusion, in meconium aspiration syndrome, 670
  - Amnion, 218f
  - Amniotic fluid, 215, 218f
    - assessment of, 336–337, 339
  - Amniotic fluid embolism, 604–605
  - Amniotic sac, rupture of, 309
  - Amniotomy, 339
    - for hypotonic uterine dysfunction, 587
    - for induction of labor, 597
  - Amniotransfusion, 605–606
  - ANA *Code of Ethics for Nurses*
    - abortion and, 15, 16
  - Analgesia
    - for circumcision, 472–473
    - common agents for, 353t
    - regional, 354–356
    - systemic
      - administration of, 352–353
  - Android pelvis, 262, 263f, 311
  - Anemia(s)
    - iron deficiency, 560
    - microangiopathic hemolytic
      - in HELLP syndrome, 526
    - in pica, 293
    - in pregnancy, 240–241
    - sickle cell, 561–562
  - Anencephaly, 700
  - Anesthesia
    - general, 357
    - regional, 354–356
  - Anocutaneous reflex (anal wink), 467
  - Anthropoid pelvis, 262, 263f, 311
  - Anthropometric measurement(s)
    - chest circumference, 459
    - head circumference, 458f, 458–459
    - length, 458
    - weight, 458
  - Antiretrovirals, for HIV infection, 118, 119
  - Anus, newborn, 465

- Apgar scoring, 449, 450t
- Aromatase inhibitors (AIs), for breast cancer, 141
- Artifacts, in fetal heart monitoring, 342
- Artificial insemination, 72, 72f
- Asphyxia  
 neonatal  
 Apgar scores in, 666  
 assessment of, 666  
 clinical signs of, 666  
 incidence of, 664  
 interventions for, 666  
 oxygen administration for, 651–652, 652f  
 in preterm and postterm newborns, 647  
 resuscitation for, 647, 650–651, 666, 666b  
 risk factors associated with, 665–666
- perinatal  
 in postterm newborn, 643  
 in small-for-gestational age newborns, 640
- Ataractics, 352, 353t, 353–354
- Attachment  
 bonding in, 401  
 commitment in, 403  
 en-face position in, 401, 401f  
 factors affecting, 402  
 parenteral role attainment and, 402  
 positive and negative behaviors in, 403, 403t  
 proximity in, 402  
 reciprocity in, 402
- Attention focusing and imagery, 351
- Attitude (fetal), 312–313  
 definition of, 312  
 full flexion, 312, 313f
- Autosomal dominant inherited disorders, 225, 225f
- Autosomal recessive inherited disorders, 225–226, 226f
- B**
- Babinski sign, 466, 469t, 471f
- Backache, in pregnancy, 281, 285
- Bacterial vaginosis  
 clinical manifestations of, 110, 110f  
 diagnosis and treatment of, 110  
 organism in, 110
- Ballottement, 236t
- Barbiturates, in labor, 352, 353t, 354
- Barlow maneuver, 466, 467f
- Barrier contraception methods, 76b, 77–78t, 80t–81t, 84–85
- Bartholin's glands, 49
- Basal body temperature (BBT) contraception, 76, 83, 83f
- Bathing newborn, 467–469  
 demonstration of, 471f  
 guidelines for, 472
- Battered woman syndrome, 193
- Battering, in cycle of violence, 191
- Behavior modification, for prevention of STIs, 124
- Beliefs, during childbearing, 32, 33t
- Benzodiazepines, in labor, 352, 353t, 354
- Bilirubin, conjugated and unconjugated, 689
- Biophysical profile of fetal well-being  
 interpretation of score, 274  
 parameters and components of, 274
- Birth  
 care providers for, 296–297  
 family-centered, 320  
 interventions in  
 amnioinfusion, 605–606  
 cesarean delivery, 607–608  
 forceps delivery, 606, 606f  
 nursing, 363, 363f  
 vacuum extractor in, 606, 607f  
 postterm, 59–596  
 preparation for, 298
- Birth calculator, 259f
- Birth center, 5, 5f, 27, 28f, 296, 296f
- Birth setting(s)  
 birthing suite in hospital, 296, 296f  
 freestanding birthing center, 296, 296f  
 home, 296  
 hospitals and delivery room, 295–296
- Birth trauma  
 in large-for-gestational age newborn, 641  
 types of, 680–681
- Birthweight variation(s), 638–643. *See also* *named*  
 appropriate-for-gestational age, 638–639  
 large-for-gestational age, 639, 641–642  
 national health goals related to, 639  
 small-for-gestational age, 639–641
- Bladder, postpartum, 398–399
- Bladder exstrophy  
 nursing care for, 707  
 pre- and postoperative, 708f  
 surgical reconstruction of, 707
- Blastocysts, 212, 214, 214f
- Bleeding gums, in pregnancy, 285
- Blinking reflex, 466, 469t
- Blood components  
 of newborn, 433, 433t  
 in pregnancy, 240–241
- Blood incompatibility  
 ABO, 527  
 Rh  
 cause of, 527  
 RhoGAM for, 528
- Blood pressure  
 postpartum, 382–383, 397  
 in pregnancy, 240
- Blood volume  
 in newborn, 433  
 in pregnancy, 240
- Body mass index (BMI)  
 calculation of, 291b  
 in pregnancy weight determination, 290–291
- Bonding, 394, 396, 401f, 401–402  
 enhancing, 476
- Bottle feeding  
 formula preparation for, 297–298  
 technique for, 298
- Bowel function  
 in newborns, 439  
 postpartum, 399
- Bowel sounds, auscultation of, 464
- Brachial plexus injury, birth-related, 680
- Brachytherapy, for breast cancer, 140
- Bradley method (partner-coached) labor and birth, 294
- Bradycardia, fetal, 344
- Braxton Hicks contractions  
 in labor, 309  
 in pregnancy, 236t, 237, 238  
 teaching for, 281  
 in third-trimester, 288
- Breast cancer  
 chemotherapy for, 141  
 clinical manifestations of, 135  
 characteristics of benign *vs.* malignant breast masses, 135b  
 defined, 133  
 diagnostic studies for, 136–138, 137f  
 genetic testing for decision making, 139  
 hormonal therapy for, 141  
 immunotherapy for, 141–142  
 interventions in  
 emotional support, 142–144  
 implementation of health-promotion/disease-prevention strategies, 145  
 nutrition, 146  
 patient education, 142  
 perioperative care, 144–145  
 management of  
 assessment in, 142  
 clinical breast examination in, 142, 143t–144t  
 nursing diagnoses in, 142  
 occurrence of, 13  
 pathophysiology of, 135–136  
 radiation therapy for, 140  
 risk at specific ages, 134t  
 risk factors for, 134–135  
 modifiable, 134  
 nonmodifiable, 134  
 screening for  
 American Cancer Society guidelines for, 145, 145t  
 breast self-examination in, 145–146, 147b  
 staging of, 136, 136t  
 surgery for  
 adjuvant therapy, 140–142  
 axillary lymph node, 139–140  
 breast-conserving (lumpectomy), 139  
 mastectomy, simple and modified, 139  
 reconstruction following, 140  
 therapeutic management of, 138–142  
 treatment plans for, 138–139  
 types of, 135–136
- Breast disorder(s)  
 benign, 128–133  
 definition of, 128  
 summary of, 129t  
 malignant, 133–147
- Breastfeeding  
 advantages and disadvantages of, 297  
 advantages of, 481b  
 assessment parameters in, 482, 483t  
 colostrum in, 481  
 education for, 483, 485  
 guidelines for, 486  
 HIV transmission in, 572

- keys to successful, 482  
 national health goals related to, 396  
 nursing care plan for difficulty with, 484–485  
 nursing diagnoses:  
   Anxiety related to breast-feeding ability and irritable, crying newborn, 484  
   Knowledge deficit related to skills involving breast-feeding, 484  
   Pain related to breast-feeding and incorrect technique for latching on, 485  
 nutrition recommendations for, 411, 411b  
 perinatal education for, 297–298  
 positioning for, 483  
 postpartum education for  
   one-on-one instruction, 412–413  
   positions, 413f  
   steps to successful, 412  
 preparation for, 297  
 recommendations for, 480–481  
 transitional milk in, 481
- Breast milk**  
 composition of, 481  
 storage and expression of, 485, 487f
- Breast pump**, 385f, 485, 487f
- Breasts**  
 anatomy and physiology of, 50  
 engorgement of, 384, 385, 413–414  
 postpartum, 398  
 in pregnancy, 239  
   care of, 275–276  
   tenderness of, 284
- Breast self-examination**  
 for cancer screening, 145–146  
 technique, 147b
- Breathing techniques, in labor**, 351–352
- Breech presentation, dystocia with**, 588–589, 593t
- Bronchopulmonary dysplasia**  
 clinical signs and symptoms of, 671  
 definition of, 671  
 etiology of, 671  
 incidence and risk factors, 671  
 interventions for, 672
- Bulbourethral glands (Cowper's glands)**, 54f, 55
- Burping**, 479, 480f
- C**
- Caffeine, effect on pregnancy**, 575t, 576
- Calories, requirement in pregnancy**, 289t, 290
- Cancer(s)**. *See also named*  
 breast, 133–147  
   as cause of death, 13  
   cervical, 168–173  
   endometrial, 173–177  
   ovarian, 177–180  
   vaginal, 180–182  
 Caput succedaneum, 462, 463f  
   birth-related, 680
- Carbohydrates, newborn metabolism of**, 437–438
- Carcinoma**  
 colloid, 135  
 definition of, 135  
 infiltrating ductal, 135  
 lobular, in situ and infiltrating, 135  
 medullary, 135
- Cardiac output, in pregnancy**, 240
- Cardiovascular disease**  
 health risk assessor for, 11, 12f  
 postmenopausal, 101  
 prevention of, 11, 13  
 risk factors for, 10–11  
 in women, 11–13
- Cardiovascular disorder(s)**  
 acquired disease, 555–557  
 chronic hypertension, 557–558  
 classification of heart disease, 553, 553t  
 clinical manifestations of, 553  
 congenital heart conditions, 553, 554t–555t, 555  
 effects on pregnancy, 552–553  
 fetal risk from, 552  
 mortality from, 552, 553
- Cardiovascular system**  
 of fetus, 432  
 of newborn, 432–433  
 postpartum, 382–383  
 of preterm newborn, 646
- Car seat, for safety**, 475
- Cell proliferative indices, in breast cancer**  
 diagnosis, 138
- Central nervous system**  
 in neonatal abstinence syndrome, 688f  
 of preterm newborn, 646
- Cephalohematoma**, 462, 463f  
 birth-related, 680
- Certified nurse-midwives (CNMs)**, 5, 296
- Cervical cancer**  
 clinical manifestations of, 169  
 definition of, 168  
 diagnosis of, 169–172  
   new technologies for, 169–170  
   Papanicolaou test in, 168, 169, 170–171  
 etiology of, 168–169  
 HPV-induced, 122  
 management of, 169–172  
 national health goals related to, 168  
 nursing care plan for, 174–175  
 nursing diagnoses:  
   Anxiety related to diagnosis and uncertainty of outcome, 174  
   Deficient knowledge related to diagnosis, prevention strategies, and treatment, 174  
   pathophysiology of, 168, 169f  
   prevention of, 172–173  
   risk factors for, 168–169  
   treatment of, 172, 173b
- Cervical cap**, 78t, 85, 88f  
 insertion/removal technique, 96
- Cervical dysplasia, cervical cancer risk from**, 168
- Cervical insufficiency**  
 causes of, 508  
 cerclage for, 508, 508f  
 management of, 508
- Cervical mucus ovulation method**, 76, 83f
- Cervicitis, infections with**, 111–113
- Cervix**  
 anatomy and physiology of, 46–47, 47f  
 in labor  
   dilation of, 308, 324  
   effacement of, 336  
 laceration in delivery, 615  
 normal, 48f  
 parous and nulliparous, 48f  
 postpartum, 381, 381f  
 in pregnancy, 239
- Cesarean birth**  
 definition of, 606  
 incisions in, 606, 607f  
 increase in, 606–607  
 indications for, 607–608  
 management of  
   postoperative, 608  
   preoperative, 608  
   vaginal birth following, 608–609
- Chadwick's sign**, 236t, 237, 239
- Chancre, of primary syphilis**, 114f
- Chemotherapy**  
 for breast cancer, 141  
 classes of drugs for, 141  
 high-dose with bone marrow/stem cell transplant, 141  
 side effects of, 141
- Chest**  
 newborn, 464, 468t  
 in prenatal physical examination, 261f, 261–262
- Childbirth**  
 in America, time line for, 6b  
 midwives for, 5  
 settings for, 5, 5f
- Childbirth education**  
 about birth settings, 295–296  
 management of, 295, 295f  
 for natural childbirth, 293–295
- Chlamydia**  
 clinical manifestations of, 110  
 diagnosis of, 110  
 effect on pregnancy/fetus/newborn, 563t  
 in high-risk groups, 112–113  
 management of, 112–113  
   P-LI-SS-IT model in, 113b  
 risk factors for, 111  
 treatment of, 111
- Choanal atresia**  
 definition of, 701–702  
 surgery for, 702
- Chorionic villus sampling (CVS)**  
 defined, 271  
 management of, 272  
 technique for, 272  
 timing of, 272
- Chromosomal abnormality(ies)**  
 numeric, 223–224  
 structural, 223, 224–225
- Chromosomes**, 212  
 defined, 221  
 in sex determination, 221
- Circumcision**, 465  
 analgesia for, 472–473  
 care following, 473–474  
 debate over, 472  
 description of, 472, 473f  
 risks and benefits of, 473

- Cleft lip, 703, 703f  
 care of newborn with, 703–704  
 description of, 703  
 risk factors for, 703
- Cleft palate  
 care of newborn with, 703–704  
 surgical correction for, 703
- Clinic hours, as barrier to care, 15
- Clitoris, anatomy and physiology of, 47f, 49, 49f
- Clomiphene citrate challenge test, for infertility, 71
- Clothing, during pregnancy, 276
- Clubfoot, congenital, 708, 708f  
 classification of, 708  
 management of, 709  
 treatment of, 709
- Coagulation, postpartum, 383
- Cocaine use  
 characteristics of cocaine-exposed newborns, 684  
 effects of  
 fetal, 577, 684  
 maternal, 577  
 on pregnancy, 575t  
 incidence of fetal exposure to, 576–577
- Coitus interruptus contraception, 84
- Cold stress, in newborns, 437  
 interventions for, 437, 438f
- Colorrhaphy, for pelvic prolapse, 157
- Colostrum, 50, 239, 481
- Colposcopy, 172
- Combined spinal-epidural (CSE) analgesia  
 advantages of, 355  
 complications of, 356  
 technique for, 355
- Communication, guidelines for, 35b
- Community, concepts of, 22
- Community-based care  
 complementary and alternative medicine in, 37t, 37–38  
 cultural issues in, 32–37
- Community-based nursing  
 care during labor and delivery, 27–28  
 challenges in, 23, 25, 25b  
 concept of community and, 22  
 employment trends in, 22  
 examples of, 22  
 interventions in, 23, 24b  
 maternal and infant services in, 26b, 26–30  
 nursing roles in, 23, 24t  
 origin of, 22  
 postpartum and newborn care, 28–30  
 practice settings for, 23, 23t  
 prenatal care in, 26–27  
 preparation for, 23  
 prevention in  
 epidemiologic approach to, 31–32  
 levels of, 30–31  
 nurse's role in, 31  
 services in, 26–27
- Community-based women's health services, 30
- Complementary and alternative medicine (CAM)  
 assessment of, 38  
 guidelines for, 38  
 management of, 37–38  
 nursing diagnoses and, 38  
 types of, 37t
- Condoms  
 female, 77t, 84–85, 86f  
 latex allergies and, 85  
 male, 77t, 84, 86f
- Conduction, in newborn heat loss, 435f, 436
- Condylomata, 121
- Congenital condition(s)  
 anencephaly, 700  
 bladder exstrophy, 707  
 choanal atresia, 701–702  
 cleft lip and palate, 703–704  
 clubfoot, 708–709  
 CNS structural defects, 698–701  
 developmental dysplasia of hip, 709–710  
 diaphragmatic hernia, 702–703  
 epispadias, 707  
 esophageal atresia and tracheoesophageal fistula, 704  
 gastrointestinal system structural anomalies, 703–706  
 gastroschisis, 704–705  
 genitourinary system structural anomalies, 706–708  
 heart disease, 695–698  
 hydrocephalus, 698, 700, 700f  
 hypospadias, 707  
 imperforate anus, 706  
 inborn errors of metabolism, 698, 699t  
 microcephaly, 700  
 musculoskeletal system structural anomalies, 708–709  
 national health goals related to, 665  
 omphalocele, 704  
 respiratory system structural anomalies, 701–703  
 spina bifida, 700–701
- Congenital diaphragmatic hernia  
 anomalies associated with, 702  
 clinical features of, 702  
 description of, 702, 702f  
 nursing care for, 702–703  
 prenatal diagnosis of, 702
- Congenital heart disease  
 classification of, 696, 697t  
 definition of, 695  
 management of  
 continuous monitoring in, 696  
 prenatal, 696  
 parents in plan of care, 696–697  
 risk factors for, 696
- Constipation  
 in pregnancy  
 first-trimester, 284–285  
 teaching guidelines for, 281  
 third-trimester, 287
- Continuous labor support  
 in pain management, 348
- Contraception  
 abortion, 84–91  
 assessment for, 93–94  
 family planning flow record in, 94, 95f  
 nursing diagnoses in, 94  
 religious beliefs and, 93, 93b  
 behavioral, 75b, 76–84  
 decision-making process in, 94  
 definition of, 75  
 emergency, 81t, 90–91, 91f, 92t  
 informed consent in, 94  
 interventions in, 94  
 management of, 93–97  
 methods of, 75b, 75–76, 77t–82t  
 nursing diagnoses in, 94  
 problems and educational needs with, 98t  
 rationale for, 75  
 sterilization, 91–93  
 teaching guidelines for, 96–97
- Contraceptive(s)  
 barrier, 75b, 84–85  
 for prevention of STIs, 124  
 implantable, 80t, 88–89, 90f  
 injectable, 79t, 88, 89f  
 oral, 85–88  
 sponge, 78t, 85  
 transdermal, 79t, 88, 89f  
 vaginal rings, 80t, 88, 90f
- Contractions. *See* Braxton Hicks contractions  
 in true *versus* false labor, 309, 309t
- Convection, in newborn heat loss, 435f, 436
- Corpus, 47f, 48
- Corpus luteum (lutein) cyst, 162
- Cortisol, in pregnancy, 244
- Costs  
 of adolescent pregnancy, 569  
 of preterm newborn, 644  
 as problem in health care, 7
- Cough reflex, 466, 469t
- Couvade syndrome, 247
- Cranial nerve trauma, birth-related, 680
- Cri du chat syndrome, 224–225
- Crowning, in second stage labor, 360, 367f
- Cultural beliefs  
 of childbearing patients, 32, 33t
- Cultural competence  
 barriers to, 36–37  
 definition of, 33–34
- Culturally competent care  
 cultural encounter in, 36, 36f  
 cultural knowledge in, 34  
 cultural self-awareness in, 34  
 cultural skills in, 35–36  
 in labor, 333, 335b
- Culture  
 as barrier to care, 15  
 characteristics of, 32–33, 34t  
 family orientation in, 33  
 language in, 33  
 personal space in, 32–33  
 time and, 32
- Cystocele, 152, 153f
- Cytomegalovirus (CMV) infection, perinatal, 562–563
- D**
- Date rape, 194–195  
 drugs in, 195
- Death of newborn  
 detachment process in, 657  
 grieving process in, 657

- Deceleration  
 defined, 345  
 interventions for, 346b  
 types of, 345f, 345–346
- Deep vein thrombosis  
 anticoagulant therapy for, 621  
 postpartum, 621, 628
- Dental care, during pregnancy, 275
- Depo-provera, 80t, 88
- Descent, in labor, 316, 316f
- Developmental dysplasia of hip (DDH), 466, 467f  
 characteristics of, 709f  
 description of, 709  
 etiology of, 709  
 nursing care for, 709  
 Pavlik harness for, 709, 710f  
 treatment of, 709
- Diabetes mellitus  
 classification of, 544–545, 545b  
 definition of, 544  
 effects on pregnancy, 545–546  
 fetal-neonatal risks with, 546  
 gestational, 544  
   antepartum interventions in, 551  
   assessment of, 550  
   definition of, 549  
   guidelines for, 551  
   intrapartum interventions in, 550–551  
   postpartum interventions in, 552  
   risk assessment for, 550  
   screening for, 549  
   self-blood glucose monitoring in, 550f  
   treatment of, 549–550  
 impact on newborns, 675  
 nursing diagnoses:  
   Anxiety related to future pregnancy  
     and its outcome secondary to  
     underlying diabetes, 548  
   Deficient knowledge related to type 1  
     diabetes, blood glucose control,  
     and effects of condition on preg-  
     nancy, 547  
 pregestational, 546  
   dietary management of, 546  
   fetal surveillance, 549  
   glycosylated hemoglobin (HbA1C)  
     level in, 546  
   insulin regimens for, 546  
   maternal surveillance, 548–549  
   nursing care plan for type 1 diabetes,  
     547–548  
   prevalence of, 544  
 Diaper area care, 469, 471–472
- Diaphragm contraceptive, 78t, 85, 87f  
 insertion/removal technique and counsel-  
 ing, 96
- Diastis recti*, 384
- Dick-Read method for labor and birth,  
 294–295
- Diet  
 healthy, in pregnancy, 288  
 in pregnancy  
   fish in, 289  
   food guide pyramid in, 290f  
   recommendations for, 289, 289t
- Dietary modification, for pelvic prolapse, 154
- Dietary reference intakes (DRIs), for iron  
 and folic acid in pregnancy, 288
- Digestion, in newborn, 439
- Discharge planning  
 for high-risk newborn, 658, 658b  
 for parents of newborn  
   immunity and immunizations, 490  
   schedule of visits, 489–490
- Disseminated intravascular coagulation  
 (DIC)  
 in abruptio placenta, 513–514, 514b  
 emergency measures for, 618  
 in postpartum hemorrhage, 616, 618
- Diuresis, postpartum, 383
- Diversity, implications for provision of  
 health care, 32
- DNA  
 composition of, 221, 221f  
 function of, 221
- DNA ploidy status, in breast cancer diagno-  
 sis, 138
- Documentation, of vaginal birth after  
 cesarean, 609
- Doppler flow studies, in fetal assessment,  
 268
- Doulas  
 during labor and birth, 5, 296–297, 320,  
 321
- Down syndrome  
 characteristics of, 223, 223f  
 screening tests for, 269
- Ductus arteriosus*, 432, 433
- Ductus venosus*, 432, 433
- Dysfunctional uterine bleeding (DUB)  
 assessment of, 64  
 clinical manifestations of, 64  
 definition of, 64  
 etiology of, 64  
 management of, 65  
 nursing care plan for, 66–67  
 nursing diagnoses in:  
   Deficient knowledge related to peri-  
     menopause and its management,  
     66  
   Fear related to current signs and symp-  
     toms possibly indicating a life-  
     threatening condition, 66  
 treatment of, 65
- Dysmenorrhea  
 assessment of, 62  
 clinical manifestations of, 62  
 definition of, 61  
 etiology of, 61–62  
 management of, 63–64  
 treatment of, 63, 63t
- Dyspnea, in pregnancy, 287
- Dystocia  
 assessment of, 592  
 causes of, 687  
 definition of, 586  
 interventions in, 592, 594f, 594–595  
 management of, 591, 593t–594t, 595  
 passageway in, 591–592  
 passenger in, 588–591  
 powers in, 587–588  
 psyche in, 592  
 risks for, 587
- E**
- Ears, newborn, 464, 468t
- Eclampsia  
 comparison with preeclampsia, 510t, 519  
 seizures in, 519, 520  
 management of, 520–521
- Ectoparasitic infections, 123
- Ectopic pregnancy  
 causes of, 503  
 clinical manifestations of, 504  
 implantation sites in, 503, 505f  
 incidence of, 503  
 management of  
   medical, 505  
   nursing, 505–506  
   surgical, 505  
 national goal for, 500  
 prevention of, 506  
 treatment of, 505
- Edema  
 dependent, in third-trimester, 287–288  
 in pregnancy, 267
- Edward syndrome, 224
- Effacement  
 in labor  
   cervical, 336  
   vaginal examination for, 336  
 in true labor, 309
- Emergency contraception (EC)  
 methods available, 90, 92t  
*versus* Mifepristone, 90–91
- Emotional disorders  
 assessment of, 629  
 interventions in, 629  
 postpartum  
   blues, 627  
   depression, 627–628  
   psychosis, 628–629
- Empowerment, in family-centered maternity  
 care, 5, 17
- Endocrine system  
 postpartum, 384–386  
 in pregnancy, 242–243
- Endometrial biopsy, 176–177  
 for infertility, 71
- Endometrial cancer  
 clinical manifestations of, 175  
 definition of, 173  
 diagnosis of, 175–176  
 etiology of, 175  
 management of, 177  
 pathophysiology of, 173  
 preventive and follow-up measures for,  
 177  
 progression of, 176f  
 risk factors for, 175  
 treatment of, 177
- Endometrial cycle  
 menstrual phase in, 53  
 proliferative phase in, 53  
 secretory phase in, 53
- Endometriosis  
 assessment of, 69  
 clinical manifestations of, 69  
 description of, 68  
 etiology of, 68  
 management of, 69

- Endometriosis (*contd.*)  
 risk factors for, 68–69  
 sites of, 68f  
 support organizations and web sites for, 70b  
 treatment of, 69, 70t
- Endometrium, 46, 47f
- Engagement  
 in initiation of labor, 309  
 in labor, 316, 316f
- Enteral feeding, of preterm newborn, 646
- Enterocoele, 152, 153f
- Epididymis, 54, 54f
- Epidural block  
 combined spinal-epidural analgesia, 355–356  
 contraindications to, 355  
 technique for, 354, 355f
- Episiotomy, 50  
 definition of, 360  
 infection prevention measures for, 409  
 infiltration analgesia for, 356  
 location of, 363f  
 nursing diagnoses and care plan for, 404  
 postpartum  
 assessment of, 400  
 infection of, 626
- Epispadias, description of, 707, 707f
- Epistaxis, in pregnancy, 285
- Epstein's pearls, 460, 463
- Ergonovine maleate, for postpartum hemorrhage, 619
- Erythema toxicum, 460, 461f
- Esophageal atresia  
 definition of, 704, 705f  
 prenatal sign of, 704  
 preoperative care in, 704  
 surgery and postoperative care for, 704  
 types of, 704
- Estrogen, 218  
 ovarian secretion of, 48, 53  
 postpartum, 384  
 in pregnancy, 245t
- Estrogen replacement therapy (ERT)  
 for menopause, 100  
 for pelvic prolapse, 154
- Ethical issues. *See* Legal and ethical issue(s)
- Evaporation, in newborn heat loss, 435f, 436
- Exercise(s)  
 postpartum, 407–408  
 guidelines for, 409  
 Kegel, 408  
 recommended, 408  
 during pregnancy, 276f, 276–277  
 guidelines for, 277
- Expulsion  
 in labor, 318  
 of placenta, 325, 615
- Extension, in labor, 316f, 318
- External rotation (restitution), in labor, 316f, 318
- Extremely low birthweight infant, 639
- Extremities, in prenatal physical examination, 262
- Eyes  
 newborn, 463–464, 468t  
 prophylaxis for ophthalmia neonatorum, 454–455, 456f
- F**
- Face, newborn, 462–463, 468t
- Face and brow presentation, dystocia with, 588, 593t
- Fallopian tubes, 47f, 48
- Family-centered birthing, 320
- Family-centered care, defined, 5–6
- Family-centered maternity care (FCMC), 4–5
- Family planning flow record, 94, 95f
- Father of newborn  
 adaptation stages of  
 expectation, 388  
 reality, 388  
 transition to mastery, 388  
 engrossment of  
 characteristics of, 387f, 387–388
- Fatigue, in pregnancy, 281, 284
- Feeding  
 newborn. *See also* Bottle feeding; Breastfeeding; Formula feeding  
 burping in, 479, 480f  
 methods, 480–486  
 timing of, 479
- Female condom  
 insertion/removal and counseling for, 97  
 teaching guidelines for, 97
- Female genital mutilation  
 cultural reasons for, 196  
 health risks from, 196  
 prevalence of, 195–196  
 types of, 196, 196b
- Female reproductive cycle(s). *See also* named  
 endometrial, 53  
 menopause in, 51  
 menstrual, 51–52, 52f  
 hormones in, 53b, 53–54  
 ovarian, 51–53
- Female reproductive system  
 breasts, 50  
 in erection, lubrication, and orgasm, 50  
 external organs, 48–50, 49f  
 internal organs, 46–48, 47f  
 postpartum adaptations of, 380–382
- Female reproductive tract  
 benign growths of, 159–163  
 cancer of. *See also* Cancer(s)  
 interventions in, 183  
 nursing assessment for, 182  
 nursing diagnoses in, 182–183  
 ovarian cysts, 161–163  
 pelvic prolapse, 152–157  
 polyps of, 159–160  
 urinary incontinence and, 157–159  
 uterine fibroids, 160–161
- Fertility awareness contraception, 76, 77t
- Fertilization, 214f
- Fetal alcohol spectrum disorder  
 characteristics of, 575, 576f  
 cognitive and behavioral problems associated with, 576b  
 risk factors for, 575
- Fetal alcohol syndrome  
 effects of, 682–683  
 incidence of, 682
- Fetal circulation, 218–219  
 function of, 219  
 placenta in, 218  
 shift to newborn circulation at birth, 432  
 shunts in, 218, 219  
 summary of, 220f
- Fetal development  
 embryonic stage, 212, 214–218  
 placenta in, 215, 218  
 placental barrier in, 215  
 summary of, 216t–217t, 217f, 218f  
 umbilical cord formation in, 215
- fetal circulation in, 218–219  
 function of, 219  
 placenta in, 218  
 shunts in, 218, 219  
 summary of, 220f
- fetal stage, 216t–217t, 218f  
 preembryonic stage, 212, 213f, 214, 214f  
 summary of, 215f
- Fetal fibronectin test, for preterm labor, 534
- Fetal heart rate  
 in gestational hypertension, 521  
 during labor, 338–343  
 measurement of, 266  
 Cardiff technique, 266b  
 Sadovsky technique, 266b  
 in oligohydramnios, 529
- Fetal heart rate monitoring  
 continuous electronic, 340–341, 342f  
 criteria for, 343  
 external, 342, 343f, 344  
 internal, 342–343, 343f  
 in first stage labor, 358, 359  
 guidelines for, 340  
 intermittent, 339–340, 340f  
 comparison with electronic monitoring, 340–341  
 locations for, 340, 341f
- Fetal heart rate patterns  
 baseline, 343–344  
 baseline variability  
 short- and long-term, 344  
 interpretation of, 343t  
 nonreassuring, 346, 346b  
 parameters for, 343  
 periodic baseline changes  
 accelerations, 346  
 decelerations, 345f, 345–346
- Fetal oxygen saturation monitoring, during labor, 346–347
- Fetal scalp monitoring, 346
- Fetal stimulation, during labor, 347
- Fetal well-being assessment  
 alpha-fetoprotein analysis in, 268–269  
 amniocentesis, 269–271, 270f, 271t  
 biophysical profile in, 274  
 chorionic villus sampling in, 271–272  
 contraction stress test, 273–274  
 Doppler flow studies in, 268  
 marker screening tests, 269  
 nonstress test, 272–273  
 percutaneous umbilical blood sampling, 272  
 ultrasonography in, 267–268, 268f
- Fetus  
 assessment during labor  
 fetal heart rate monitoring in, 338–343

- fetal oxygen saturation monitoring, 346–347
    - fetal scalp sampling, 346
    - fetal stimulation, 347
  - descent and presenting part, 336
  - excessive size and abnormalities of, 591, 594t
  - Fibroadenomas
    - characterization of, 129t, 130
    - clinical manifestations of, 130, 132, 132f
    - diagnosis of, 130
    - treatment and nursing care for, 132
  - Fibrocystic breast changes
    - characterization of, 128, 130f
    - clinical manifestations of, 128–129
    - diagnosis of, 129
    - nursing care for, 129
    - nursing care plan for, 131–132
    - nursing diagnoses in:
      - Deficient knowledge related to fibrocystic breast changes and appropriate care measures, 131
      - Pain related to changes in breast tissue, 131
      - symptom relief in, 130
      - treatment of, 129, 129t
  - Fine-needle aspiration biopsy
    - for breast cancer, 136–137
    - in fibrocystic breast changes, 129
  - Flatulence with bloating, in pregnancy, 281, 286–287
  - Flexion, in labor, 316, 316f, 318
  - Folic acid, requirement in pregnancy, 288, 289t
  - Follicle-stimulating hormone (FSH), 51, 53
    - in pregnancy, 243
  - Follicular cysts, 162
  - Fontanels
    - abnormal, 462
    - normal, 461–462
  - Foramen ovale*, 432–433
  - Forceps delivery
    - forceps in, 606, 606f
    - indications for, 606
  - Formula feeding
    - commercial formulas for, 481–482
    - education for, 485–486
    - equipment needed for, 482
    - formula preparation for, 297–298, 482
    - guidelines for, 487
    - positions for, 485, 486
  - Fractures, birth-related, 680
  - Fragile X syndrome, 225
  - Fundus, postpartum assessment of, 398, 398f
- G**
- Gag reflex, 466, 469t
  - Galactosemia, 699t
  - Gametogenesis, 213f
  - Gardnerella vaginalis*, 110
  - Gas exchange, from fetal to newborn, 432
  - Gastrointestinal system
    - in neonatal abstinence syndrome, 688f
    - in newborns, 439
    - postpartum, 383–384
    - in pregnancy, 239–240
    - of preterm newborn, 646
  - Gastroschisis
    - definition of, 704
    - nursing care in, 705–706
    - risk factors for, 705
    - surgical repair of, 706
  - General anesthesia, indications and procedures for, 357
  - Genes
    - homozygous and heterozygous, 221–222
    - mutation of, 221, 222f
  - Genetic disorders
    - autosomal dominant, 225, 225f
    - autosomal recessive, 225–226, 226f
    - counseling and, 227, 229–230
    - multifactorial, 226–227
    - prenatal tests for, 227, 228t–229t
    - X-linked, 226, 226f
  - Genetics
    - advances in, 219–221
    - basics of, 221f, 221–222, 222f
    - chromosomal abnormalities in, 223–225
    - ethical, legal, social ramifications of, 220–221
    - Human Genome Project, 219–220
    - inheritance patterns in
      - autosomal, 225–226
      - multifactorial, 226–227
      - X-linked, 226
    - management in
      - genetic counseling, 227, 229–230
      - genetic history in, 227, 227b
      - prenatal tests in, 227, 228t–229t
      - prenatal tests for genetic disorders, 227, 228t–229t
      - profiling in, 219–220
  - Genetic testing
    - in breast cancer, 138–149
    - psychological distress following, 139
  - Genital herpes simplex virus infection
    - diagnosis of, 114
    - neonatal infection from, 113
    - primary episode, 113, 113f
    - recurrent infection, 113–114
    - transmission of, 113
    - treatment of, 114
  - Genitalia, newborn, 465, 465f, 468t
  - Genital ulcers
    - infections in, 113–115
    - management of, 115
  - Genitourinary system structural anomalies
    - bladder exstrophy, 707, 708f
    - epispadia, 707, 707f
    - hypospadias, 707
    - problems and concerns in, 706–707
  - Gestational age
    - assessment of, 451–453
      - neuromuscular maturity in, 451–452, 452f
      - physical maturity in, 451, 452f
    - in classification of newborn, 453
  - Gestational age variation
    - assessments for, 647
    - interventions for, 647–655
    - management of, 646–647
    - oxygenation promotion in, 647, 650
    - postterm newborn, 643–644
  - Gestational diabetes
    - national health goal for, 500
  - Gestational hypertension
    - assessment of
      - ankle clonus in, 523
      - blood pressure in, 522
      - deep tendon reflexes in, 522–523, 523t
      - for edema, 522
      - fetal heart rate in, 521
      - rollover test, 521
      - serum magnesium levels in, 524
      - tolerance–hyperbaric test, 522
    - classification of, 518
    - clinical manifestations of
      - eclampsia, 519, 520t
      - preeclampsia, 519, 520t
    - eclampsia
      - acronym for intervention in, 526b
      - interventions for, 526
    - edema in
      - dependent, 522
      - pitting, 522
    - HELLP syndrome and, 524
    - management of
      - antepartum, 520–521
      - intrapartum, 521
      - postpartum, 521
    - medications used with preeclampsia and eclampsia, 525
    - pathophysiological events in, 519
    - risk factors for, 519
  - Gestational trophoblastic disease, 506–508
    - cancer risk with, 507
    - clinical manifestations of, 507
    - features of, 507
    - hydatiform mole, 506
    - incidence of, 506
    - interventions in, 507–508
  - Gestational variations
    - postterm, 643–644
    - preterm newborn, 644–646, 648–650
  - Glucose, in pregnancy, 244, 244b
  - Gonorrhea
    - clinical manifestations of, 112, 112f
    - diagnosis of, 112
    - effect on pregnancy/fetus/newborn, 563t
    - in high-risk groups, 112–113
    - management of, 112–113
      - P-LI-SS-IT model in, 113b
    - organism in, 111–112
    - site of, 111–112
    - treatment of, 112
  - Goodell's sign, 236, 236t, 239
  - Grasp reflexes, 466, 469t, 471f
  - Gravida, 260
  - Grieving
    - after spontaneous abortion, 503
    - after still birth, 602–603
  - Group B *Streptococcus*
    - effect on newborns, 566
    - management of, 566
    - treatment of, 566
  - Growth hormone (GH), in pregnancy, 243
  - Gynecoid pelvis, 262, 263f, 311
- H**
- Habituation, in newborns, 442
  - Harlequin sign, 460, 461f

- Head and neck  
in prenatal physical examination, 261, 261f
- Head size, 461–462, 468t  
abnormalities in, 462  
variations in, 462
- Head trauma, birth-related, 680–681
- Health indicators, 7, 11b
- Healthy People 2010  
goals for maternal and infant health, 8  
objectives of, 7–8
- Hearing, screening in newborn, 464, 477, 479b
- Heart, newborn, auscultation of, 464
- Heartburn  
in pregnancy, 240  
in third-trimester, 287
- Heart rate  
of newborn, 433  
in pregnancy, 240
- Hegar's sign, 236, 236t, 238
- HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome  
clinical manifestations of, 526–527  
diagnosis of, 527  
in preeclampsia, 526  
treatment of, 527
- Hematologic condition(s)  
iron deficiency anemia, 560  
sickle cell anemia, 561–562  
thalassemia, 561
- Hemolytic disease of the newborn  
ABO incompatibility in, 690, 691  
assessment of, 691–692  
clinical manifestations of, 690  
comparison of RH and ABO incompatibility, 691t  
diagnostic tests for, 691  
interventions in  
exchange transfusion, 692, 693  
phototherapy, 692–693  
skin care, 693  
Rh blood incompatibility in, 690–691, 691f
- Hemorrhage  
fetal periventricular–intraventricular, 672–673  
postpartum, 614–620  
risk for, 396b
- Hemorrhoids, 281, 286
- Hepatic system function  
in newborns, 437–439  
bilirubin conjugation, 438–439  
carbohydrate metabolism, 437–438  
iron storage, 437
- Hepatitis A virus (HAV)  
clinical manifestation and diagnosis of, 122  
transmission of, 122  
treatment of, 122
- Hepatitis B virus (HBV)  
clinical manifestations and diagnosis of, 122  
effect on newborns, 564  
goals of therapy in, 565  
prevention of, 564–565  
risk for contracting, 564  
screening for, 564  
transmission of, 122, 563  
treatment of, 123  
vaccination for, 564
- HER-2/neu genetic marker  
for breast cancer, 138
- Heroin use  
fetal effects of, 577, 685  
neonatal abstinence syndrome from, 577
- Herpes simplex virus (HSV). *See also* Genital herpes simplex virus infection  
management of, 564  
perinatal transmission to infants, 564  
subtypes of, 564
- HIV (human immunodeficiency virus)  
infection  
activity of, 571  
AIDS and, 116, 571  
assessment of, 573  
birthing method and, 573  
clinical manifestations of, 117  
diagnosis of, 117  
drug therapy for, 117–118  
adherence to, 118  
compliance with, 120  
education about, 118, 120–124  
epidemiology of, 116, 117  
fetal and neonatal effects of, 116  
incidence and prevalence of, 571  
interventions in  
cesarean birth, 573–574  
family planning, 574  
informational, 573  
for psychosocial sequelae of, 573  
maternal and fetal/newborn risks from, 572  
nursing care plan for, 119–120  
nursing diagnoses in:  
Knowledge deficit related to HIV infection and possible complications, 120  
Risk for infection related to positive HIV status and inconsistent compliance with antiretroviral therapy, 119  
perinatal transmission of, 571–572  
pregnancy and childbirth care, 121  
pregnancy in, 571–574  
prevalence of, 116  
prevention of, 120–121  
referrals in, 121  
screening and diagnosis of, 572  
sexually transmitted infections and, 573  
stages of infection from, 571, 572t  
transmission of  
breastfeeding, 572  
modes in, 571  
perinatal, 571–572  
treatment of, 117–118, 572–573  
in women, 116
- Homan's sign, postpartum, 400, 401f
- Home birth, 27–28
- Home ovulation predictor kits, 71
- Home uterine activity monitoring  
for preterm labor, 534–535, 535f
- Home visits  
diversity and, 25  
for newborn care, 29  
planning for, 23, 25b  
postpartum, 29, 419
- Hormonal contraception, 76b, 79t, 85–88, 88f
- Hormonal therapy, for breast cancer, 141
- Hormone receptor status, in breast cancer  
diagnosis, 138
- Hormone replacement therapy (HRT)  
for menopause, 100
- Hot flashes  
definition of, 99  
pharmacologic management of, 100  
treatment of, 99–100
- Hot tubs and saunas, 275
- Human chorionic gonadotropin (hCG), 215  
biochemical marker for pregnancy, 237  
in pregnancy, 245t
- Human chorionic somatomammotropin, in pregnancy, 245t
- Human papilloma virus (HPV)  
cervical cancer risk from, 168  
clinical manifestations of, 121, 121f  
diagnosis of, 121–122  
effect on pregnancy/fetus/newborn, 563t  
genital warts (condylomata) from, 121  
management of, 122  
treatment of, 122
- Human placental lactogen (hPL), 215, 218
- Human trafficking  
victim identification in, 197b  
victims of, 197
- Hydatiform mole, 506
- Hydramnios  
clinical manifestations of, 528  
consequences of, 529  
defined, 528  
incidence of, 528  
treatment of, 528–529
- Hydrocephalus, 700f  
associated defects in, 698  
definition of, 698  
management of, 698, 700  
postoperative, 700  
preoperative, 698, 700  
ventriculoperitoneal shunt for, 698
- Hydrotherapy, in labor, 348
- Hymen, 49, 49f
- Hyperbilirubinemia  
bilirubin in, 689  
definition of, 687  
in large-for-gestational age newborn, 642  
normal  
physiologic jaundice in, 689–690  
pathologic jaundice, 690–691  
pathophysiology of, 687, 689  
risk factors for, 689
- Hyperemesis gravidarum  
assessment of, 517  
causes of, 515  
clinical manifestations of, 515–516  
incidence of, 515  
interventions in, 517–518  
medications for, 516  
minimizing, 517  
risk factors for, 515  
treatment of, 516–517



- Hyperpigmentation  
in pregnancy, 241–242
- Hypertensive disorders. *See also* Gestational hypertension  
classification of, 518t
- Hypertonic uterine dysfunction, 587, 593t
- Hypoglycemia  
in large-for-gestational age newborn, 641–642  
newborn, 489  
in postterm newborn, 643  
in small-for-gestational age newborns, 640–641
- Hypophysis, 243
- Hypospadias, 707, 707f
- Hypothermia  
in postterm newborn, 643–644  
in small-for-gestational age newborns, 640
- Hypothyroidism, congenital, 699t
- Hypotonic uterine dysfunction, 587, 593t
- Hysterectomy  
abdominal, 161  
interventions for, 162b  
for uterine fibroids, 161  
vaginal, 161
- Hysterosalpingogram, 71–72, 72f
- I**
- Idiopathic thrombocytopenia purpura  
postpartum hemorrhage in, 616, 618
- Immune system  
newborn, 439–440  
in pregnancy, 245  
of preterm newborn, 646
- Immunity, in newborns, 440
- Immunization  
in discharge preparation, 490  
for hepatitis B, 564  
of newborns, 475  
postpartum, 418  
during pregnancy, 279, 280b  
CDC guidelines for, 280b
- Immunoglobulins, 440
- Immunotherapy, for breast cancer, 141–142
- Imperforate anus, 706, 706f  
surgical intervention for, 706
- Implantable contraceptives, 80t, 88–89, 90f
- Implantation, 214f
- Inborn errors of metabolism, 698, 699t  
screening tests for, 476–477
- Incest  
of, 194
- Incontinence, in pregnancy, 281, 282, 283–284
- Indigestion, in third-trimester, 287
- Induction of labor  
medical indications for, 321  
rate of, 321
- Infant abduction prevention, 474–475
- Infants of diabetic mothers  
characteristics of, 679f  
common problems of, 675, 676t–677t, 679t  
hyperbilirubinemia, 675–676, 676t, 677t  
hypocalcemia, 675, 676t, 679
- hypoglycemia, 675, 676t, 677, 678  
hypomagnesemia, 675, 676t  
polycythemia, 675, 677t  
respiratory distress syndrome, 676t. *See also* Respiratory distress syndrome (RDS)  
laboratory values for, 679t  
nursing care plan for, 678–679  
nursing diagnoses:  
Risk for impaired gas exchange related to respiratory distress secondary to fetal hyperinsulinemia inhibiting pulmonary surfactant production and delaying lung maturation, 678  
Risk for injury related to hypoglycemia secondary to maternal gestational diabetes, 678
- Infection(s)  
maternal and fetal effects of, 562  
neonatal sepsis, 693–694  
newborn  
assessment of, 694  
classes of, 694  
interventions in, 695  
manifestations of, 694  
prevention of, 695  
risk factors for, 694  
postpartum, 621–627  
assessment for, 625–626  
client teaching, 626–627  
mastitis, 625, 626f  
metritis, 622  
nursing diagnoses:  
Acute pain related to infectious process, 623  
Ineffective thermoregulation related to bacterial invasion, 623  
Risk for impaired parental/infant attachment related to effects of postpartum infection, 624  
prevention of, 626, 695  
risk factors for, 623, 624b  
signs and symptoms of, 625t  
urinary tract, 622  
wound infections, 622, 626f  
postpartum risk for, 396b  
in pregnancy  
cytomegalovirus, 562–563  
group B *Streptococcus*, 566  
hepatitis B virus, 564–565  
herpes simplex virus, 564  
parvovirus B19, 565–566  
rubella, 563–564  
sexually transmitted, 563t  
toxoplasmosis, 566–567  
varicella zoster virus, 565  
in preterm and postterm newborns  
prevention of, 653–654  
prevention of  
in newborn, 475  
sexually transmitted. *See* Sexually transmitted infection(s)
- Infertility  
assessment of, 70–71  
definition of, 69  
in endometriosis, 69  
etiology of, 69–70
- female  
diagnostic tests for, 71  
factors in, 70  
treatment of, 72, 73f
- male  
factors in, 70  
semen analysis for, 71  
management of, 72–73  
organizations and web sites for, 75b  
risk factors for, 70  
treatment of  
financial concerns in, 74–75  
options for, 74t
- Infiltration analgesia, in episiotomy, 356
- Informed consent  
in contraception, 94  
to vaginal birth after cesarean, 609
- Inheritance, of gender, 213f
- Inhibin A, Down syndrome marker, 269
- Injectable contraceptives, 79t, 88, 89f
- Insulin secretion, in pregnancy, 244, 244b
- Integumentary system  
newborn, 440  
postpartum, 384  
in pregnancy, 241–242
- Intensity-modulated radiation therapy (IMRT)  
for breast cancer, 140
- Intimate partner violence  
background of, 190–191  
consequences of, 190f  
definition of, 190  
incidence of, 190  
myths and facts about, 192, 192t  
during pregnancy, 193
- Intra-abdominal pressure, in labor, 319
- Intraductal papilloma  
clinical manifestations of, 132  
definition of, 132  
diagnosis of, 132  
treatment and nursing care for, 132–133
- Intrauterine devices (IUDs)  
complications of, 91b  
description of, 89–90  
devices available, 90
- Intrauterine fetal demise, grief response to, 602–603
- Intrauterine fetal surgery, ethical issues in, 16
- Intrauterine growth restriction (IUGR)  
asymmetric, 640  
small-for-gestational age newborn and, 639–640  
symmetric, 639
- In vitro fertilization, 72, 72f
- Involution, uterine, 380–381, 381f
- Iron  
requirements in pregnancy, 288, 289t  
storage in newborns, 437
- J**
- Jaundice  
in newborns, 437, 488  
assessment for, 488  
bilirubin conjugation and, 438  
causes of, 438–439  
phototherapy for, 488–489  
risk factors for, 438

- Jaundice (*contd.*)  
 pathologic  
   causes of, 690  
   hemolytic disease of the newborn in, 690–691  
   kernicterus in, 690  
 physiologic  
   in breast-fed *versus* bottle-fed newborn, 689–690  
   from breastfeeding, 690  
   contributing factors in, 689
- K**  
 Karyotype, 221, 222f  
 Kegel exercises, 153–154  
   postpartum, 409  
   purpose of, 154  
   teaching, 310  
   teaching of, 156  
 Kernicterus, 690  
 Klinefelter syndrome, 223–224
- L**  
 Labia, anatomy and physiology of, 47f, 49, 49f  
 Labor  
   admission assessments in, 332–335  
     for culturally competent care, 333, 335b  
   documentation form for, 334f  
   laboratory studies, 335  
   maternal health history, 333  
   physical examination, 333, 335  
   ambulation in, 348, 349f, 350t–351t  
   augmentation of, 596  
     assessment in, 599  
     interventions in, 599, 602  
   cardinal movements of, 315–316, 316f  
   delivery sequence in, 317f  
   dysfunctional. *See* Dystocia  
   evaluation of progress of, 335–347  
     fetal assessments in, 338–347  
     maternal assessments in, 335–339  
   factors affecting. *See also named factor*  
     partners, 320–321  
     passageway, 310–311  
     passenger, 311–318  
     patience, 321  
     philosophy, 320  
     position, 319–320  
     powers, 318–319  
   first stage, 323, 323b  
     active, cervical dilatation, 324  
     assessments during, 358, 359t  
     documentation of care in, 357–358, 358f  
     interventions in, 357, 358  
     latent, cervical effacement, 323–324  
     management of, 357–359  
     nursing care plan for, 361–362  
     nursing diagnoses:  
       Anxiety related to labor and birth process and fear of the unknown related to client's first experience, 361  
       Pain related to effects of contractions and cervical dilatation and events of labor, 361  
       Risk of infection related to vaginal exams following rupture of membranes, 362  
       positioning during, 360  
     fourth stage, restorative, 323, 323b, 325  
     assessment in, 369–370  
     interventions in, 370  
     management of, 369–370  
   induction of, 321  
     assessment in, 599  
     cervical ripeness and, 596, 597t  
     drugs used in, 597–599, 598t  
     indications and contraindications to, 596  
     interventions in, 599, 602  
     mechanical, 597  
     nonpharmacologic, 596–597  
     nursing diagnoses:  
       Anxiety related to induction of labor and lack of experience with labor, 600  
       Pain related to uterine contractions, 600  
       Risk for injury (maternal or fetal) related to induction procedure, 601  
     nursing plan for, 600–601  
     oxytocin for, 598–599  
     risks with, 596  
     surgical, 597  
     teaching for, 602  
   initiation of, 308  
     bloody show, 309  
     Braxton Hicks contractions in, 309  
     cervical changes in, 308  
     lightening in, 308  
     rupture of membranes, 309  
   management of  
     first stage, 357–359  
     fourth stage, 369–370  
     second stage, 359–368  
     third stage, 368–370  
   normal, 586–587  
   pain management in, 321–322, 347–357.  
     *See also* Pain, management of  
       general anesthesia, 357  
       regional analgesia/anesthesia, 354–356  
       systemic analgesia in, 352–354  
   physiologic responses to  
     fetal, 322  
     maternal, 322  
   position changes in, 348, 349f, 350t–351t  
   postterm, 595–596  
   precipitous, 588, 593t  
   premonitory signs of, 308–309  
   prenatal education for, 321  
   preparation for, 298  
   preterm. *See* Preterm labor  
   second stage  
     assessment in, 360  
     birth in, 363  
     crowning in, 324  
     documentation of progress in, 364f–366f  
     expulsive, 323, 323b  
     interventions in, 362–363  
     management of, 359–368  
     pelvic phase of, 324  
     perineal lacerations in, 359–360  
     perineal phase of, 324  
     placental separation in, 325  
     positioning in, 360, 362  
     pushing in, 324, 359  
     stages of, 322–325, 323b  
     third stage, placental, 323, 323b  
       assessment in, 368–369  
       interventions in, 369  
       management of, 368–370  
     transition, 324  
     true *versus* false, 309t, 309–310  
 Labor, delivery, and recovery (LDR) rooms, 5, 5f  
 Lactation  
   definition of, 385  
   dietary recommendations during, 289, 289t  
   nutrition recommendations for, 411, 411b  
   physiology of, 385, 385f  
   suppression of, 414  
 Lactational amenorrhea method (LAM) of contraception, 77t, 84  
 Lactose intolerance, 292  
 Lamaze method for labor and birth, 294  
 Language  
   as barrier care, 14  
 Large-for-gestational age (LGA) newborns  
   assessment of, 642  
   characteristics of, 641  
   definition of, 641  
   interventions for, 642–643  
   maternal factors in, 641  
   problems of, 641–642  
 Legal and ethical issue(s)  
   abortion, 15, 16  
   fetal therapy, 16  
   substance abuse, 16, 17b  
 Leg cramps  
   in pregnancy, 281, 285–286  
 Leopold's maneuvers  
   defined, 337  
   performance of, 338–339  
   purpose of, 337–338, 339  
 Leukorrhea, in pregnancy, 139, 285  
 Lie (fetal), 313, 313f  
 Lifestyle modifications  
   for pelvic prolapse, 154  
 Lightening  
   in labor, 308  
   in pregnancy, 139  
 Linea nigra, 242, 242f  
 Lochia, 380  
   definition of, 381  
   postpartum assessment of, 399f, 399–400  
   postpartum discharge of, 325  
   stages of, 381  
 Low birthweight infant, 639  
 Lumpectomy, 139  
 Lunelle injection, 79t, 88, 89f  
 Lung cancer, 13  
 Lungs, newborn, 434  
 Luteinizing hormone (LH), 51, 53  
 Lymphedema, after axillary lymph node surgery, 139–140
- M**  
 Macrocephaly, 462  
 Macrosomia  
   diagnosis of, 591  
   labor and birth in, 591

- Magnesium sulfate  
in preeclampsia and eclampsia, 525  
prophylactic in HELLP syndrome, 527
- Magnetic resonance mammography (MRM), 136
- Male condom  
insertion/removal and counseling for, 96–97
- Male reproductive system  
accessory glands in, 54f, 55, 55f  
in erection, orgasm, and ejaculation, 56  
external organs in, 55f, 55–56  
internal organs in, 54f, 54–55
- Malignant breast disorder. *See* Breast cancer
- Mammary duct ectasia  
clinical manifestations of, 133  
definition of, 133  
diagnosis of, 133  
treatment and nursing care for, 133
- Mammography  
description of, 136, 137f  
in fibrocystic breast changes, 129  
preparing for, 137
- Maple syrup urine disease (MSUR), 699t
- Marijuana  
effect on pregnancy, 575t  
fetal effects of, 577, 683–684  
maternal effects of, 577
- Massage, in labor, 351, 352f
- Mastitis, 415  
causes of, 625  
clinical manifestations and diagnosis of, 133, 133f  
definition of, 133  
postpartum, 398  
risk factors for, 133  
signs and symptoms of, 625t  
treatment and nursing care for, 133, 134
- Maternal and Child Health Bureau (MCHB)  
programs and initiatives of, 10, 10b
- Maternal and women's health care  
current trends, 5–6  
management of, 16–17  
past trends, 4–5
- Maternal and women's health care perspectives  
future trends/needs, 7
- Matin–Bell syndrome, 225
- McRobert's maneuver, in shoulder dystocia, 590, 590f
- Meconium, 439, 469  
aspiration of  
by postterm newborn, 644  
in small-for-gestational age newborns, 641
- Meconium aspiration syndrome  
assessment of, 670  
definition of, 669  
interventions in, 670  
risk factors for, 670
- Medications  
FDA pregnancy risk classification of, 280b  
during pregnancy, 280  
over-the-counter and herbal agents, 280
- Melanocyte-stimulating hormone (MSH), 243
- Membranes, spontaneous rupture of, 309
- Meningocele, 700, 700f
- Menopause  
assessment of, 99  
bodily system effects of, 98–99  
cardiovascular disease in, 101  
definition of, 97–98  
hot flashes and night sweats in, 99–100  
management of, 101  
osteoporosis in, 100–101  
perimenopause and, 98  
symptoms of, 99b  
treatment of  
medical, 99  
urogenital changes in, 100
- Menstrual cycle  
hormones in, 53b, 53–54  
summary of, 52f
- Menstrual disorder(s)  
amenorrhea, 60–61  
dysfunctional uterine bleeding, 64–65, 166  
dysmenorrhea, 61–64  
endometriosis, 68–69, 70b, 70t  
premenstrual syndrome, 65, 67–68  
vocabulary in, 60b
- Menstruation  
corpus luteum of, 47f  
postpartum, 386
- Mental abuse, 192
- Metabolic disturbances  
in neonatal abstinence syndrome, 688f
- Methadone  
fetal effects of, 685
- Methamphetamines  
fetal effects of, 684
- Methotrexate  
in ectopic pregnancy
- Methylgonovine  
for postpartum hemorrhage, 619
- Metritis  
definition of, 622  
risk for, 622  
signs and symptoms of, 625t
- Microcephaly, 462  
definition of, 700  
risk factors for, 700
- Midwives, 296
- Mifepristone (RU-486)  
for abortion, 91
- Milia, 460, 461f
- Misoprostol (RU 486), in spontaneous abortion, 504
- Mitosis, 212, 213f  
of stoma cells, 213f
- Molar pregnancy. *See* Gestational trophoblastic disease
- Molding, 462, 462f
- Mongolian spots, 460, 461f
- Monosomies, 224
- Mons pubis  
anatomy and physiology of, 49, 49f
- Mood swings, in pregnancy, 246
- Morning sickness. *See also* Nausea and vomiting  
in pregnancy, 240
- Moro reflex, 466, 469t, 470f
- Mortality,  
intrauterine, 602–603
- Mortality rate  
fetal, for abruptio placenta, 512  
infant, 8–9, 9f  
past, 4  
maternal, 8–9, 9f, 10  
in neonatal sepsis, 693–694
- Morula, 212
- Motor maturity, in newborns, 442
- Mouth, newborn, 463, 468t
- Multifactorial inherited disorders, 226–227
- Multiple gestation, 591b, 594t  
clinical manifestations of, 530  
dysfunctional labor and birth with, 590, 593t  
management of, 530  
monozygotic and dizygotic twins in, 529–530, 530f  
treatment of, 590–591
- Musculoskeletal system  
postpartum, 384  
in pregnancy, 241, 242f
- Myelomeningocele  
definition of, 700  
hydrocephalus and, 700, 701f  
management of, 701f  
risk factors for, 700–701
- Myomectomy, 161
- Myometrium, 46, 47f
- N**
- Nagele's rule, for estimated date of birth, 259
- Narcotic use/abuse  
effect on pregnancy, 575t  
maternal risk from, 577
- Natural childbirth method(s)  
Bradley, 294  
Dick-Read, 294–295  
Lamaze, 294
- Nausea and vomiting  
in pregnancy, 240, 281, 284. *See also* Hyperemesis gravidarum
- Neck, newborn, 464, 468t
- Necrotizing enterocolitis, 673–674  
assessment of, 674  
incidence of, 674  
interventions in, 674–675  
necrosis or perforation in  
surgery for, 674  
predisposing risk factors for, 674b
- Neisseria gonorrhoeae*, 111
- Neonatal abstinence syndrome, 577. *See also* Substance use/abuse  
assessment in, 687, 688f  
consequences of, 685–686  
defined, 685  
interventions in, 687  
manifestations of, 686b  
pharmacologic treatment of, 687  
symptoms of, 686  
teaching care of infant in, 689
- Neonatal period. *See also* Newborn  
definition of, 432

- Neonatal sepsis
  - assessment of, 694–695
  - interventions in, 695
  - mortality rate in, 693–694
  - risk factors for, 694
- Neural tube defects, 698
  - prevention of, 31
- Neurologic system
  - newborn
    - reflexes in, 441
    - sensory capabilities in, 440–441
- Nevus flammeus (port wine stain), 460, 461f
- Newborn. *See also* Neonatal period
- Newborn period
  - assessment in
    - abdomen, 464–465
    - Apgar scoring in, 449, 450t
    - chest, 464
    - early, 457–467
    - ears, 464
    - extremities, 465–466
    - eyes, 463–464
    - face, 462–463
    - genitalia, 465, 465f
    - of gestational age, 451–453
    - head, 461–462
    - immediate, 449–453
    - length, 449, 450f
    - mouth, 463
    - neck, 464
    - of neurologic status, 466–467, 467f
    - nose, 463
    - perinatal history in, 457
    - physical examination in, 457–467
    - skin, 460–461, 461f
    - spine, 466
    - summary in, 468t
    - vital signs, 451, 459
    - weight, 449–450, 451f
  - interventions in
    - early, 467–474
    - eye prophylaxis, 454–455, 456f
    - for identification, 453–454, 454f
    - immediate, 453–456
    - suctioning for airway patency, 453
    - thermoregulation maintenance, 455–456, 456f
    - vitamin K prophylaxis, 454, 455, 455f
- Newborns
  - acquired disorders in. *See* Acquired disorder(s)
  - assessment of
    - summary of, 468t
  - bathing, 467–469, 471f, 472
  - behavioral adaptations of, 441–443
  - bonding with, 394, 396, 401f, 401–402
  - breastfeeding, 480–481, 481b, 482–485, 483t, 487f
  - circumcision care, 472–474, 473f
  - common concerns in
    - hypoglycemia, 489
    - physiologic jaundice, 488–489
    - transient tachypnea of the newborn, 488
  - congenital disorders in. *See* Congenital conditions(s)
  - diaper area care in, 469, 471–472
  - discharge preparation for, 489
  - elimination patterns in, 469
  - follow-up care of, 489–490
  - formula feeding, 481–482, 485–486, 487
  - heat loss in
    - mechanisms of, 435f, 436–437
    - predisposition to, 434
  - immediate care of, 363, 368
  - immunization of, 475
  - infection prevention in, 475
  - neurobehavioral responses in, 442–443
  - nutritional needs of, 480
  - nutrition promotion for, 477–478
  - physiologic adaptations of, 432–441
  - safety considerations
    - car, 475, 475f
    - environmental, 474–475
    - screening tests for, 476–477, 478t
    - security systems for, 368, 368f
    - sleep care, 475–476
    - suctioning of, 363, 363f
    - umbilical cord care, 472, 473
    - weaning and introduction of solid foods, 486–488
- Nicotine use
  - effect on pregnancy, 575t
  - fetal effects of, 576
  - maternal effects of, 576
- Night sweats, menopausal, 99–100
- Nipples, supernumerary, 464
- Norplant, 80t, 88–89, 90f
- Nose
  - newborn, 463, 468t
  - in pregnancy
    - nasal stuffiness of, 285
- Nutrition
  - newborn. *See also* Feeding
    - needs of, 480
    - physiologic changes and, 477, 479
    - solid foods in, 487–488
    - weaning and, 486–487
  - postpartum
    - recommendations for, 411, 411b
  - in pregnancy, 288–289, 290f, 290t
    - cultural variations and restrictions and, 292
    - dietary recommendations for, 289, 289t
    - food guide pyramid for, 290f
    - lactose intolerance and, 292
    - nursing diagnosis: Imbalanced nutrition, less than body requirements
      - related to nausea, 283
    - promotion of adequate, 291
    - for vegetarians, 292
  - promotion of in preterm and postterm newborns, 653
- O**
  - Obesity
    - prediction of long-term, 408
  - Obstetric emergencies
    - amniotic fluid embolism, 604–605
    - placental abruption, 604
    - umbilical cord prolapse, 603–604
    - uterine rupture, 604
  - Obstetric history, prenatal visit, 260, 260f
  - Oligohydramnios
    - amnioinfusion in, 605–606
    - causes of, 529
    - clinical manifestations of, 529
    - definition of, 529
    - fetal heart rate in, 529
  - Omphalocele
    - definition of, 704, 706f
    - nursing care for, 705–706
    - risk factors for, 705
    - surgical repair of, 706
  - Oogenesis, 213f
  - Ophthalmia neonatorum, 112
    - prevention of, 454–455, 456f
  - Opiate withdrawal, danger to fetus, 577
  - Opioids, in labor, 352, 353t, 354
  - Oral contraceptives (OCs)
    - advantages and disadvantages of, 89t
    - assessment for, 87–88
    - combination, 85–86
    - complications of, 88, 89b
    - extended regimens of, 87
    - mechanism of action of, 86–87
    - progestin-only, 87
  - Orientation, in newborns, 442
  - Ortolani maneuver, 466, 467f
  - Osteoporosis
    - pharmacologic management of, 101
    - postmenopausal, 100
    - risk factors for, 100
    - screening for, 101
    - skeletal changes with, 100, 101f
  - Outpatient clinics
    - for postpartum and newborn care, 29
  - Ovarian cancer
    - clinical manifestations of, 178–179
    - definition of, 177, 178f
    - diagnosis of, 179
    - etiology of, 177–178
    - management of, 180
    - metastatic sites of, 179f
    - risk factors for, 178
    - survival rates for, 180, 180t
    - treatment of, 179–180
  - Ovarian cycle
    - follicular phase, 51
    - luteal phase, 52–53
    - ovulation in, 51
  - Ovarian cysts
    - description of, 161, 162f
    - management of, 163
    - treatment of, 163, 163b
    - types of, 162–163
  - Ovaries, 47f, 48
    - in pregnancy, 239
  - Overheating, in newborns, 436–437
  - Overweight, postpartum, 408
  - Ovulation
    - cervix in, 48
    - home predictor kits for, 71
    - postpartum, 382, 386
  - Oxygen administration
    - for asphyxia in newborn, 651–652, 652f
  - Oxytocin
    - for cervical ripening and labor induction, 598–599
      - administration of, 598–599
      - advantages of, 599

- in labor, 308
  - in lactation, 385, 386
  - in milk ejection in breast-feeding, 243
  - in postpartum hemorrhage, 619
  - in uterine contractions in birth, 243
- P**
- Pain management**
- in circumcision, 472–473
  - JCAHO standards for, 347
  - in labor, 321–322, 347–357
  - in newborns, 655b, 655–656
  - nonpharmacologic, 347–352
    - gate control theory in, 347–348
  - pharmacologic, 353t, 362–356
  - postpartum, 397, 398f
- Pancreas, in pregnancy, 243–244**
- Papanicolaou (Pap) test**
- age guidelines for, 172, 172t
  - Bethesda system for specimen classification, 172, 172b
  - for cervical cancer, 168, 169
  - collection of smear for, 170–171
  - colposcopy for abnormal results, 172
  - patient strategies to optimize results, 171
- Para, 260**
- Parents**
- management of bereaved, 657–658
  - of preterm and postterm newborns
    - anxiety reduction for, 656–657
  - retinopathy of prematurity and, 672
- Parvovirus B19**
- clinical manifestations of, 565
  - management of, 566
  - risks to fetus, 565
  - transmission of, 565
  - treatment of, 565–566
- Passageway (birth)**
- in dysfunctional labor and birth, 591–592, 594t
  - pelvis, 310–311
  - soft tissue, 311
- Passenger (fetus), 311–318. *See also* Fetus**
- attitude, 312–313, 313f
  - in cardinal movements of labor, 315–316, 316f, 318
  - in dysfunctional labor and birth, 588–591, 593t
    - breech presentation, 588–589
    - excessive fetal size and abnormalities, 591
    - face and brow presentation, 588
    - multiple gestation, 590–591, 591b
    - persistent occiput posterior position, 588
    - shoulder dystocia, 589–590, 590f
  - engagement, 315
  - lie, 313, 313f
  - position, 314–315, 315b
  - presentations, 313–314, 314f
  - skull, 311–312, 312f
  - station, 315, 315f
- Patau syndrome, 224, 224f**
- Patient-controlled epidural analgesia (PCE), 356**
- pump delivery of, 356f
- Pediculosis pubis (pubic lice), 123, 123f**
- nursing care for, 123
  - treatment of, 123
- Pelvic examination**
- genitalia in
    - external, 262
    - internal, 262
  - pelvic measurements in, 263, 264f
  - pelvic shape in, 262–263, 263f
- Pelvic inflammatory disease (PID)**
- causes of, 115
  - clinical manifestation of, 115
  - definition of, 115, 115f
  - diagnostic criteria for, 115
  - gonorrhea and, 112
  - management of, 116
  - risk factors for, 116
  - treatment of, 116
- Pelvic prolapse**
- clinical manifestations of, 152–153, 154f
  - degrees of, 152
  - description of, 152
  - incidence and etiology of, 152
  - nursing diagnoses:
    - Knowledge deficit related to causes of structural disorders and treatment options, 156
    - Pain related to relaxation of pelvic support and elimination difficulties, 155
  - treatment of
    - nonsurgical, 153–157
    - nursing care plan for, 155–156
    - nursing considerations in, 153
    - surgical, 157
  - types of, 152
- Pelvis**
- bony, 310, 310f
    - inlet, 310
    - outlet, 311
    - true and false, 310
  - in dysfunctional labor and birth, 591
  - linea terminalis in*, 310, 310f
  - shape of
    - types of, 311
- Penis**
- anatomy and physiology of, 55
- Percutaneous umbilical blood sampling (PUBS)**
- management for, 272
  - risks with, 272
- Perinatal drug abuser. *See* Substance use/abuse**
- Perineum**
- anatomy and physiology of, 49–50
  - care during pregnancy, 275
  - laceration of, 400
  - postpartum, 382, 400
- Periodic breathing, in newborns, 434**
- Periventricular–intraventricular hemorrhage**
- classification of, 673
  - definition of, 672
  - incidence and risk factors for, 673
  - signs and symptoms of, 673
  - supportive care in, 673
- Persistent occiput posterior position, dystocia with, 588, 593t**
- Persistent pulmonary hypertension of the newborn**
- definition of, 670–671
  - incidence and risk factors in, 671
  - oxygen therapy for, 671
  - resuscitation for, 671
- Pessaries**
- for pelvic prolapse, 154, 156
    - indications for, 156–157
    - types of, 156, 157f
- PGE2, dinoprostone**
- for spontaneous abortion, 504
- Phenylketonuria (PKU), 699t**
- screening for, 476, 477f, 478t
- Phototherapy**
- in newborns with jaundice, 692f, 692–693
  - teaching for home administration, 693
- Physical abuse, 192**
- Physical examination, head-to-toe, in prenatal visit, 260, 261f**
- Physiologic anemia of pregnancy, 240–241**
- Pica**
- defined, 293
  - iron deficiency and, 293
  - in pregnancy, 292–293
  - substances consumed in, 293
- Pituitary gland, in pregnancy, 243**
- Placenta, 212**
- expulsion of, 325, 615
  - functions of, 215
  - separation of, 325
    - monitoring of, 368
  - in third stage of labor
    - assessment of, 369, 369f
- Placenta accreta, 615**
- Placental hormones, 215, 218**
- postpartum, 384–385
  - in pregnancy, 245, 245t
- Placenta previa**
- assessment in, 510
  - classification of, 509f
  - clinical manifestations of, 509–510
  - interventions in, 510
  - nursing care plan for, 511–512
  - nursing diagnoses:
    - Anxiety related to threats to self and fetus, 512
    - Ineffective tissue perfusion (fetal and maternal) related to blood loss, 511
    - risk factors for, 509
- Platypeloid pelvis, 262–263, 263f, 311**
- Polycystic ovarian syndrome (PCOC)**
- characterization of, 162
  - clinical manifestations of, 163
  - management of, 163
  - treatment of, 163, 163b
- Polycythemia**
- in large-for-gestational age newborn, 642
  - in postterm newborn, 644
  - in small-for-gestational age newborns, 641
- Polyplody, 223, 224**
- Polyp(s)**
- cervical, 159f, 159–160
  - clinical manifestation and diagnosis of, 160
  - endocervical, 159f, 159–160
  - endometrial, 159f, 160

- Polyp(s) (*contd.*)  
 etiology of, 159  
 management of, 160  
 treatment of, 160
- Position (fetal), 315b  
 definition of, 314  
 determination of, 314–315
- Position (maternal)  
 in labor, 319–320  
 changes in, 348, 349f, 350t–351t  
 summary of common, 350t–351t
- Position (uterine)  
 in initiation of labor, 308
- Postcoital testing  
 for infertility, 71, 72b
- Postpartum blues, 417, 627
- Postpartum complication(s)  
 hemorrhage, 614–618, 619–620  
 infection, 621, 623–627  
 nursing care plan for, 623–624  
 thromboembolic conditions, 618, 620–621
- Postpartum depression  
 definition of, 627  
 incidence of, 628  
 manifestations of, 628b  
 risk factors for, 628
- Postpartum hemorrhage  
 assessment for, 616–617  
 causes of, 614–618  
 definition of, 614  
 disseminated intravascular coagulation in, 616, 618  
 drugs for control of, 619–620  
 fundal massage for, 617, 618  
 idiopathic thrombocytopenia purpura and, 616, 618  
 interventions in, 617–618  
 perineal hematoma in, 617, 617f  
 risk factors for, 615b  
 thrombosis and, 616  
 tissue in, 615  
 trauma and, 615  
 uterine atony in, 614, 615  
 uterine distension in, 615  
 uterine tone in, 615  
 von Willebrand disease and, 616, 617
- Postpartum period  
 assessment in, 396–403  
 for bonding and attachment, 401f, 401–402  
 for danger signs, 397b  
 emotional, 401  
 for hemorrhage risk, 396b  
 for infection risk, 396b  
 physical, 396–401  
 blues in, 417, 627  
 breast care in  
 for engorgement, 413–414  
 for lactation suppression, 414  
 for mastitis, 415  
 for sore nipples, 414  
 complications in. *See* Postpartum complication(s)  
 contraception counseling in, 410  
 cultural influences during, 395b  
 discharge preparation, 417–418  
 challenges for families following, 418b  
 immunization status in, 418  
 feeding choice and education in  
 bottle feeding, 411–412  
 breastfeeding, 412  
 follow-up care in, 28–30  
 home visit, 29, 419  
 outpatient, 418–419  
 telephone, 418  
 initiation of, 325  
 letting-go phase, 387  
 management of  
 attachment behaviors in, 394, 396  
 bonding behaviors in, 394, 396  
 maternal adaptations to  
 physiologic, 380–386  
 psychological, 386–387  
 nursing care plan for, 404–405  
 nursing diagnoses:  
 Impaired tissue integrity related to episiotomy, 404  
 Pain related to episiotomy, sore nipples, and hemorrhoids, 404  
 Risk for ineffective coping related to mood alteration and pain, 405  
 nutrition in, 410–411, 411b  
 paternal adaptations to, 387–388  
 promoting family adjustment for role changes in  
 grandparents, 416–417  
 parental, 415–416, 416f  
 siblings, 416, 417f  
 promotion of activity, rest, and exercise, 407–408  
 promotion of comfort in, 403, 405  
 analgesics for, 407  
 cold and heat in, 405  
 for constipation, 407  
 geribottle in, 406  
 sitz baths for, 406, 406f  
 topical preparations, 406–407  
 for voiding, 407  
 risk for complications, 396b  
 safety in  
 infant, 409–410  
 maternal, 409  
 self-care measures in, 408–409  
 sexuality counseling in, 410  
 taking-hold phase, 387  
 taking-in phase in, 386–387, 387f  
 woman at risk in, national health goals for, 614
- Postpartum psychosis, 628–629
- Postterm newborns  
 assessment of, 647  
 characteristics of, 643  
 complications in, 643–644, 647  
 interventions in, 647
- Postterm pregnancy  
 assessment of  
 antepartum, 595  
 intrapartum, 595  
 definition of, 595  
 delivery decisions in, 595  
 fetal risks with, 595  
 interventions in, 596  
 maternal risks with, 595
- Posttraumatic stress disorder (PTSD)  
 following rape, 200  
 following sexual abuse, 197
- Postural changes of pregnancy, 241, 242f
- Powers in labor  
 in dystocia, 587–588, 593t  
 intra-abdominal pressure, 319  
 uterine contractions, 318–319
- Precipitous labor, 588, 593t
- Pregnancy. *See also* named condition or population  
 in adolescence. *See* Adolescent pregnancy  
 backache in, 281, 285  
 Braxton Hicks contractions in, 281, 288  
 breast tenderness in, 284  
 constipation in  
 first trimester, 284–285  
 teaching in, 281  
 third trimester, 287  
 third-trimester, 287  
 cravings in, 285  
 danger signs of  
 first trimester, 298  
 second trimester, 298  
 third trimester, 298–299  
 dietary recommendations in, 289, 289t  
 discomforts of, 280  
 nursing care plan for, 282–283  
 nursing diagnoses:  
 Impaired urinary elimination related to frequency secondary to physiologic changes of pregnancy, 282  
 teaching guidelines for, 281  
 third-trimester, 287–289
- edema in  
 dependent, 287–288
- fatigue in, 281, 284
- fetal well-being assessment in, 267–274
- flatulence with bloating in, 281, 286–287
- follow-up visits in  
 fetal heart rate measurement in, 266, 266t  
 fetal movement determination in, 265–266, 266b  
 fundal height measurement in, 265, 265f  
 intervals and assessments in, 266–267
- heartburn/indigestion in, 287
- hemorrhoids in, 281, 286
- high-risk, 267  
 abruptio placenta, 512–515  
 bleeding, 500–515  
 blood incompatibility, 527–528  
 disseminated intravascular coagulation in, 514, 514b  
 ectopic, 503–506  
 gestational diabetes, 527  
 gestational hypertension, 518–526  
 gestational trophoblastic disease, 506–508  
 HELLP syndrome, 526–527  
 hydramnios, 528–529  
 hyperemesis gravidarum, 515–518  
 multiple gestation, 529–530, 530f  
 oligohydramnios, 529  
 placenta previa, 509–512  
 premature rupture of membranes, 530–532

- preterm labor, 532–536, 537–538
    - risk assessment for, 500
    - risk factors for, 501b
    - spontaneous abortion, 501–503, 504
  - infection screening tests in, 266t, 267
  - intimate partner violence during, 193
  - leg cramps in, 281, 285–286
  - leukorrhea in, 285
  - maternal emotional responses to
    - acceptance, 246
    - ambivalence, 246
    - body image change, 246–247
    - introversion, 246
    - mood swings, 246
  - maternal role tasks in, 247
  - nasal stuffiness, bleeding gums, epistaxis, 285
  - nausea and vomiting in, 281, 284
  - nutritional needs in, 288–293
    - cultural variations and restrictions and, 292
    - first-trimester, 280–285
    - lactose intolerance and, 292
    - nursing diagnosis: Imbalanced nutrition, less than body requirements related to nausea, 283
    - pica and, 292–293
    - requirements in, 288–289
    - second-trimester, 285–286
    - third-trimester, 287–289
    - vegetarians, 292
  - nutritional promotion in, 291
  - objective signs of, 236–238
  - overweight in, 291
    - and partner, 247
  - perinatal education and
    - about care providers, 296–297
    - for bottle of breastfeeding, 297–298
    - childbirth education classes in, 293–295
    - for danger signs of pregnancy, 298–299
    - for labor and birth, 298
  - physiologic adaptations during, 238–245
    - general body system, 239–245
    - reproductive system, 237–238
  - positive signs of, 238
  - preconception care
    - defined, 254
    - key areas in, 254–255
    - screening and counseling checklist for, 256f
  - pre-existing conditions in
    - cardiovascular disorders, 552–557
    - chronic hypertension, 557–558
    - diabetes mellitus, 544–552
    - hematologic, 560–562
    - infections, 562–567
    - respiratory, 558–560
  - prenatal care
    - national health goals related to, 254
  - prenatal visit
    - comprehensive health history in, 255, 257f–258f, 259
    - estimated date of birth in, 259f, 259–260
    - laboratory tests in, 263, 264t, 265
    - obstetric history in, 260, 260b
    - physical examination in, 260–263
    - reproductive history in, 259–260
  - psychosocial adaptations during, 246–248
  - self-care promotion in, 274–280
    - clothing in, 276
    - employment during, 278
    - exercise in, 276f, 276–277
    - immunizations, 279, 280b
    - medications in, 279, 280, 280b
    - personal hygiene in, 275–276
    - sexual activity and sexuality in, 277–278
    - sleep and rest in, 277
    - travel during, 278–279, 279f
  - and sexuality, 247
  - shortness of breath and dyspnea, 287
  - and siblings, preparation for, 248, 248f
  - signs and symptoms of, 236t, 236–238
  - special populations at risk
    - adolescent, 567–570
    - age over 35 years, 570–571
    - HIV positive status, 571–574
    - perinatal drug abuser, 574–579
  - subjective signs of, 236
  - tests for, 23, 237t
  - trimesters in, 236
  - underweight in, 290–291
  - urinary frequency or incontinence in
    - first-trimester, 281, 283–284
    - nursing diagnosis, 282
  - varicosities of vulva and legs, 281, 286, 286f
  - weight gain in, 289–291, 290t
    - at 35 years or older
      - preconception visit for, 570
      - risk reduction in, 571
      - risks in, 570
- Premature rupture of membranes (PROM)**
- assessments of, 531b, 531–532
  - cause of, 531
  - clinical manifestations of, 531
  - complications of, 530
  - diagnostic tests for, 531
  - incidence of, 530–531
  - interventions in, 532
  - teaching guidelines for, 532
- Premenstrual dysphoric disorder (PMDD)**
- definition of, 65
  - diagnostic criteria for, 65, 67
  - management of, 67–68
  - treatment of, 67, 68b
- Premenstrual syndrome (PMS)**
- assessment of, 67
  - clinical manifestations of, 65, 67
  - description of, 65
  - diagnostic criteria for, 65
  - etiology of, 65
  - management of, 67–68
  - treatment of, 67, 68b
- Prenatal care**
- in community-based nursing, 26–27
  - mortality rate reduction and, 10
  - national health goals related to, 254
- Prenatal education**
- for labor and birth, 321
- Prepuce**
- anatomy and physiology of, 47f, 49, 49f
- Presentation(s)**
- breech, 313, 314f
  - cephalic, 313, 314f
  - landmark parts in, 314
  - shoulder, 313
- Preterm infants**
- developmentally supportive care for, 656
  - infection prevention in, 653–654
  - pain management in
    - assessment of, 655
    - goals for, 655–656
    - guidelines for, 655b
    - pharmacologic, 656
  - prevention of complications in, 654
  - promoting parental coping in, 656–657
  - stimulation for, 654, 654f
- Preterm labor, 299**
- assessment of, 534
  - clinical manifestations of, 533
  - corticosteroids for, 536
  - definition of, 532
  - diagnosis of, 534
    - tests in, 534–535, 535f
  - interventions in, 535–536
  - medications used in, 536, 537–538
  - prevention of, 533–534, 535
  - rate of, 532
  - risk factors for, 532, 533b
  - tocolytic drugs for, 536–538
  - treatment of, 533
- Preterm newborns**
- assessment of, 647
  - body systems of, 644–645
  - characteristics of, 644, 645f
  - costs of, 644
  - definition of, 644
  - increase in, 644
  - interventions in, 647
  - nursing care plan for, 648–650
  - nursing diagnoses:
    - Ineffective thermoregulation related to lack of fat stores and hypotonia resulting in extended positioning, 649
    - Ineffective breathing pattern related to immature respiratory system and respiratory distress, 649
    - Risk for imbalanced nutrition: less than body requirements related to poor sucking and lack of glycogen stores necessary to meet the newborn's increase metabolic demands, 648
- Preterm premature rupture of membranes (PPROM)**
- definition of, 531
- Prevention**
- in community-based nursing
    - epidemiologic approach in, 31–32
    - primary, 30–31
    - secondary, 31
    - tertiary, 31
- Progesterone, 218**
- corpus luteum secretion of, 53–54
  - ovarian secretion of, 48
  - in pregnancy, 245t
- Prolactin, 50**
- in lactation, 385, 386

- Prostaglandin (PGF-2 $\alpha$ )  
for postpartum hemorrhage, 619
- Prostaglandins  
in labor, 308  
in menstrual cycle, 54  
secretion during pregnancy, 244
- Prostate gland, 54f, 55
- Protein requirement, in pregnancy, 288
- Pseudomenstruation, newborn, 465
- Ptyalism, in pregnancy, 239
- Pudendal nerve block, 356, 356f
- Pulmonary embolism  
assessment for signs and symptoms of, 620–621  
emergency measures for, 621  
postpartum, 620, 621
- Pulse, postpartum, 382, 397
- Pulse oximetry, fetal, 346–347
- Pulses, newborn, 459
- Q**
- Quickening, 247
- R**
- Race  
infant and maternal mortality rates and, 9, 10
- Radiation, in newborn heat loss, 435f, 436
- Radiation therapy  
for breast cancer, 140  
advances in, 140  
side effects of, 140
- Rape  
acquaintance, 194  
date, 194–195  
definition of, 194  
hospital treatment of survivors, 193–194  
nursing diagnosis: Rape-trauma syndrome related to report of recent sexual assault, 199  
nursing plan for, 199–200  
pregnancy prevention for survivors, 201  
recovery from, 198, 198t  
short- and long-term effects of, 194  
statutory, 194
- Rectocele, 152, 153f
- Rectus abdominis muscles, 384
- Reflexes of newborn, 466–467, 470f–471f  
appearance and disappearance of, 469t
- Regional analgesia/anesthesia  
in labor  
combined spinal-epidural analgesia, 355–356  
epidural block, 354–355, 355f  
local infiltration, 356  
patient-controlled epidural analgesia, 356  
pudendal nerve block, 356, 356f  
spinal analgesia/anesthesia, 356
- Relaxin, 218  
in pregnancy, 245t
- Renal system  
newborn, 439  
in pregnancy, 241  
of preterm newborn, 646
- Reproductive issue(s)  
contraception, 75–95  
infertility, 69–75  
menopause, 97–101  
menstrual disorders, 60–69
- Reproductive system  
female. *See* Female reproductive system  
male. *See* Male reproductive system
- Respiration  
of newborn, 434, 459–460  
postpartum, 397
- Respiratory conditions  
asthma, 558–559  
tuberculosis, 559–560
- Respiratory distress  
in preterm or postterm newborns  
causes of, 651  
management of, 652
- Respiratory distress syndrome (RDS)  
assessment of, 668–669  
Silverman-Anderson index in, 668, 668f  
definition of, 667  
incidence of, 667  
interventions in, 669  
mechanical ventilation in, 669f  
oxygen therapy for, 669  
pathophysiology of, 667  
risk factors for, 667  
surfactant replacement therapy for, 669
- Respiratory system  
in neonatal abstinence syndrome, 688f  
of newborn, 434  
postpartum, 384  
in pregnancy, 241  
of preterm newborn, 645–646
- Resuscitation  
for asphyxia, 650  
for neonatal asphyxia, 666, 666b  
for persistent pulmonary hypertension of the newborn, 671  
procedure for, 651, 651b
- Retinopathy of prematurity, 651–652, 652f  
incidence and risk factors for, 672  
prevention of, 672  
stages of, 672
- Rh (D) immunoglobulin  
in spontaneous abortion, 504
- Rooting reflex, 466, 469t, 471f
- Rotation  
external, 316f, 318  
internal, 316f, 318
- Rubella  
management of, 563–564  
transmission to fetus, 563
- S**
- Safety  
car seat for, 475  
environmental, 474–475
- Salivary estriol test  
for preterm labor, 534
- Scabies  
care for, 123
- Screening tests  
newborn  
conditions in, 478t  
for genetic and inborn errors of metabolism, 476–477  
hearing, 477, 479b  
for PKU, 476, 477f, 478t
- Scrotum  
anatomy and physiology of, 55f, 55–56
- Sedative use  
effect on pregnancy, 575t  
maternal and fetal consequences of, 577–578
- Selective estrogen receptor modulators (SERMs)  
for breast cancer, 141  
for menopause, 99
- Self-quieting ability of newborns, 442
- Seminal vesicles, 54f, 55
- Sentinel lymph node biopsy  
for breast cancer, 137–138
- Sexual abuse, 192  
characteristics of, 194  
childhood, 194  
definition of, 194  
effects of, short- and long-term, 194  
female genital mutilation, 195–196  
human trafficking, 197  
incest, 194  
myths and facts about, 195t  
rape, 193, 194–195
- Sexual activity and sexuality  
during pregnancy, 277–278
- Sexually transmitted infections  
affecting pregnancy, 563t
- Sexually transmitted infections (STIs)  
CDC classification of, 108b  
with cervicitis, 111–113  
with genital ulcers, 113–115  
HIV, 116–121  
human papillomavirus, 121–122  
pelvic inflammatory disease, 115–116  
prevention and control of, 108  
prevention of, 123–124  
behavior modification in, 124  
contraception in, 124  
primary, 124  
secondary, 124  
risk to women, 108  
teenagers at risk for, 108  
vaccine-preventable  
ectoparasitic, 123  
hepatitis A and hepatitis B, 122–123  
with vaginal discharge, 108–111  
management of, 110–111
- Sexual violence  
impact of, 197–198  
management of, 198–204
- Shoulder dystocia, 589–590, 590f, 593t
- Sitz baths, for perineal healing, 400, 406, 406f
- Skene's glands, 49
- Skin variations, in newborns, 460–461
- Skull, 312f  
diameters of, 312, 312f  
fontanelles, 311, 312  
fracture of, birth-related, 681  
molding of, 312  
sutures of, 311–312
- Sleep  
newborn, 475–476  
during pregnancy, 277



- Small-for-gestational age (SGA) newborn  
 assessment of, 642  
 characteristics of, 640  
 factors contributing to, 640b  
 interventions for, 642  
 intrauterine growth restriction and,  
 639–640  
 problems of, 641–642
- Social behaviors, of newborns, 442–443
- Social issue(s)  
 access to care, 13–15  
 poverty, 13
- Soft tissue dystocia, 591–592
- Sperm production, 54
- Spina bifida  
 definition of, 700  
 meningocele in, 700, 701f  
 myelomeningocele in, 700–701, 701f
- Spinal (intrathecal) analgesia/anesthesia,  
 356
- Sponge, contraceptive, 78t, 85
- Spontaneous abortion  
 categories of, 501, 502t  
 causes of, 501  
 grieving following, 503  
 management of, 501, 503  
 medications used with, 504  
 rate for, 501
- Standard days method (SDM) contracep-  
 tion, 83–84, 84f
- Stations (fetal), 315, 315f  
 definition of, 315
- Statutory rape, 194
- Stepping reflex, 466, 469t, 470f
- Stereotactic needle-guided biopsy  
 for breast cancer, 137
- Sterilization  
 for contraception, 91–92  
 tubal ligation, 92f, 92–93  
 vasectomy, 93, 93f
- Stomach, newborn, 439
- Stool characteristics, newborn, 469
- Stork bite, 460, 461f
- Strawberry hemangioma, 461, 461f
- Stress incontinence, 408  
 definition of, 158  
 treatment of, 159
- Stress test(s)  
 for fetal well-being  
 contraction stress, 273–274  
 nonstress, 272–273
- Striae gravidarum, 384  
 in pregnancy, 242
- Subarachnoid hemorrhage  
 birth-related, 680–681
- Subdural hemorrhage  
 birth-related, 681
- Subinvolution of uterus, 615
- Substance exposure  
 national health goals related to, 544
- Substance use/abuse, 681–682. *See also*  
 Neonatal abstinence syndrome  
 alcohol. *See* Alcohol use/abuse  
 assessment of, 578, 578b, 579b  
 common substances abused during preg-  
 nancy, 575t  
 alcohol, 575–576, 682–683  
 caffeine, 576  
 cocaine, 576–577, 684  
 marijuana, 577  
 nicotine, 576  
 opiates and narcotics, 577  
 sedatives, 577–578  
 counseling and education, 578–579  
 ethical and legal implications of, 16, 17b  
 fetal effects of, 574  
 heroin, 685  
 impact of addiction in, 574–575  
 marijuana, 683–684  
 maternal effects of, 574  
 methadone, 685  
 methamphetamines, 684  
 neonatal abstinence syndrome from,  
 685–688  
 perinatal, 574  
 substances in, 682b  
 teratogenic effect of, 574  
 tobacco and nicotine, 683  
 toxicology screen for, 578
- Sucking reflex, 466, 469t, 470f
- Suctioning  
 in meconium aspiration syndrome, 670  
 of newborn, 363, 363f, 453
- Suffocation, prevention of, 475–476
- Suprapubic pressure, in shoulder dystocia,  
 590, 590f
- Symptothermal contraception, 83
- Syphilis  
 clinical manifestations of, 114, 114f  
 definition of, 114  
 diagnosis of, 114–115  
 effect on pregnancy/fetus/newborn, 563t  
 primary, 114  
 screening in pregnancy, 264t  
 secondary, 114  
 tertiary, 114  
 treatment of, 115
- T**
- Tachycardia  
 fetal, 344  
 postpartum, 382, 397
- Technology equipment  
 for home care, 29
- Telephone consultation  
 for postpartum and newborn care, 29
- Temperature  
 of newborn  
 assessment of, 459  
 postpartum assessment of, 397
- Teratogen, definition of, 574
- Testes  
 anatomy and physiology of, 54, 54f
- Testosterone production, 54
- Thalassemia, 561
- Theca-lutein cysts, 162
- Therapeutic touch, in labor, 351
- Thermoregulation  
 definition of, 434  
 neural thermal environment and, 437  
 in newborns, 434, 437  
 cold stress in, 437  
 heat loss and, 434  
 thermogenesis in, 437  
 promotion in preterm and postterm new-  
 borns, 652–653
- Thrombotic condition(s)  
 postpartum  
 assessment for, 620–621  
 causes of, 620  
 deep venous thrombosis, 620, 621  
 interventions for, 621  
 prevention of, 620  
 pulmonary embolism, 620, 621  
 superficial venous thrombosis, 618, 621  
 thrombophlebitis, 618, 620–621  
 thrombosis, 616
- Thyroid gland, in pregnancy, 243
- Thyroid-stimulating hormone (TSH)  
 in pregnancy, 243
- Tobacco and nicotine use, effect on fetus,  
 683
- Tocolytic drugs, for preterm labor, 533,  
 536–538
- Tonic neck reflex, 466, 469t, 470f
- Toxoplasmosis  
 fetal effects of, 566  
 prevention of, 566–567
- Tracheoesophageal fistula  
 association with esophageal atresia, 704  
 definition of, 704, 705f
- Transdermal patch, contraceptive, 79t, 88,  
 89f
- Transient tachypnea of the newborn, 488  
 cause of, 666–667  
 interventions for, 667
- Transportation, access to care and, 14
- Transvaginal ultrasound  
 for endometrial cancer, 177  
 for preterm labor, 534
- Transverse rectus abdominis myocutaneous  
 (TRAM) flap breast reconstruction,  
 140
- Trastuzumab (Herceptin), for breast cancer,  
 141–142
- Travel  
 during pregnancy, 278, 279  
 seat belt use in, 279, 279f
- Treponema pallidum*, 114
- Trichomonas vaginalis*, 109, 110
- Trichomoniasis  
 clinical manifestations of, 110, 110f  
 diagnosis of, 110  
 effect on pregnancy/fetus/newborn, 563t  
 parasite in, 109  
 treatment of, 110
- Trimester  
 in pregnancy, 236
- Triple-marker screening, for Down syn-  
 drome, 269
- Trisomy 18 (Edward syndrome), 224
- Trisomy(ies)  
 Down syndrome, 223, 223f  
 Klinefelter syndrome, 223–224  
 trisomy 13, 224, 224f  
 trisomy 18, 224
- Trisomy 13 (Patau syndrome), 224, 224f
- Trophoblasts, 212, 214
- Truncal incurvation reflex, 466, 467, 469t
- Tubal ligation, for contraception, 92f, 92–93
- Turner syndrome, 224

- U**
- Ultrasonography
    - in fetal assessment, 267, 268f
    - in fibrocystic breast changes, 129
  - Umbilical cord, 218f
    - care in newborn, 472, 473
    - formation of, 215
    - inspection of, 465
  - Urge incontinence
    - definition of, 158
    - treatment of, 158–159
  - Urinary frequency
    - in pregnancy
      - nursing diagnosis: Impaired urinary elimination related to frequency secondary to physiologic changes of pregnancy, 282
      - teaching guidelines for, 281
  - Urinary incontinence
    - definition of, 157–158
    - management of, 159
    - pathophysiology of, 158
    - teaching guidelines for, 159
    - treatment of, 158–159
    - types of, 158
  - Urinary meatus, 55, 56f
  - Urinary retention
    - postpartum, 383
  - Urinary system
    - postpartum, 383
  - Urinary tract infections
    - postpartum, 622
    - signs and symptoms of, 625t
  - Urogenital system, in menopause, 100
  - Uterine artery embolization, 161
  - Uterine atony, 383, 614
  - Uterine contractions
    - assessment of, 337, 337f
    - parameters for, 319
    - electronic monitoring of, 337
    - home uterine activity monitoring of, 337
    - measurement of with intrauterine pressure catheter, 319
    - phases of, 318, 319f
    - postpartum, 381
    - work of, 318
  - Uterine fibroids (leiomyomas)
    - clinical manifestations and diagnosis, 160f, 160–161
    - definition of, 160
    - management of
      - medical, 161
      - nursing, 162
      - surgical, 161
    - predisposition for, 160
  - Uterine prolapse, 152, 153f
  - Uterus
    - anatomy and physiology of, 46, 47f
    - postpartum, 380–381, 398
    - postpartum hemorrhage and
      - inversion of, 615
      - subinvolution of, 615
    - in pregnancy, 237f, 237–238
    - prolapse of, 152, 153f
    - rupture of during labor, 604
- V**
- Vacuum extraction, 607f
    - indications for, 606
  - Vagina
    - anatomy and physiology of, 46, 47f
    - atrophy during menopause, 100
    - postpartum, 381–382
      - lubricants for, 382b
    - in pregnancy, 239
  - Vaginal birth after cesarean (VBAC), 608–609
    - contraindications to, 609
    - management of, 609
  - Vaginal cancer, 180–182
    - clinical manifestations and diagnosis of, 181
    - definition, 180
    - etiology of, 181
    - management of, 181
    - risk factors for, 181
    - survival rate for, 181
    - treatment of, 181
    - types of, 180–181
  - Vaginal examination
    - in labor, 336, 336f
      - for dilation and effacement of cervix, 336
      - for fetal descent and presenting part, 336
      - first stage, 358
      - for membrane integrity, 336–337
      - second stage, 360
  - Vaginal hysterectomy
    - for uterine prolapse, 157
  - Vaginal rings
    - contraceptive, 80t, 88, 90f
    - insertion/removal technique and counseling for, 96, 97f
  - Vaginitis
    - definition of, 108
    - organisms in, 108
    - prevention of, 111
  - Varicella zoster virus (VZV)
    - in newborns, 565
    - placental transmission of, 565
  - Varicosities, of vulva and legs, 281, 286, 286f
  - Vascular spiders, in pregnancy, 242
  - Vas deferens, 54f, 55, 55f
  - Vasectomy, for contraception, 93, 93f
  - Vasopressin (ADH), in pregnancy, 243
  - Venous thrombosis
    - deep, 620, 621
    - superficial, 620, 621
  - Venous vasculosis (strawberry hemangioma), 461, 461f
  - Vernix caseosa, 461
  - Very low birthweight infant, 639
- Vestibule**
- anatomy and physiology of, 49, 49f
- Violence.** *See also* Abuse
- continuum from generation-to-generation, 191
  - cycle of, 191, 192b
  - intimate partner. *See* Intimate partner violence
  - national health goals related to, 191
  - sexual. *See* Sexual abuse
- Vital signs**
- in labor, 335, 335f
  - in newborns, 451, 459–460, 468t
  - in postpartum assessment, 397
  - in prenatal visit, 260, 260f
- Vitamin K prophylaxis, 454, 455, 455f**
- von Willebrand disease, postpartum hemorrhage in, 616, 617**
- Vulva, anatomy and physiology of, 48, 49f**
- Vulvar cancer, 181f**
- clinical manifestations and diagnosis of, 182
  - definition of, 181
  - etiology of, 181–182
  - management of, 182
  - risk factors for, 182
  - treatment of, 182
  - types of, 182
- Vulvovaginal candidiasis, 108–109, 109f**
- clinical manifestations of, 109, 109f
  - diagnosis of, 109
  - prevention of, 109
  - treatment of, 109
- W**
- Weaning, 486**
- Weight gain**
- during pregnancy
    - distribution of, 290t
    - maternal, 289–290
    - prepregnancy body mass index and, 290, 291b
- Withdrawal method of contraception, 84**
- Women's health**
- policies for improving, 13
  - report card on, 10–11, 11b
- Women's health care**
- community-based, 30
  - national health goals related to, 32
  - prevention in, 30–31
- Working**
- during pregnancy, 278
- Wound infections**
- postpartum, 622
  - signs and symptoms of, 625t
- X**
- X-linked inherited disorders, 226, 226f
- Z**
- Zona pellucida, 212
  - Zygote, 212, 231f
    - fertilization and tubal transport of, 214f











